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ABSTRACT 
 
 
 Nuclear receptors (NRs) constitute a major class of drug targets in the treatment 
of various cancer types. NRs respond to cellular signals and become activated upon 
ligand binding to transcriptionally modulate expression of target genes. NR4A1 (Nur77) 
is a member of the NR4A family of nuclear receptors and displays an oncogenic profile 
in many cancer models. It is often upregulated in adult solid malignancies and is known 
to promote cell proliferation and survival. Knockdown studies of NR4A1 in cancer cell 
lines result in decreased cell growth and angiogenesis and increased apoptosis, suggesting 
NR4A1 is an oncogenic protein. Due to the elevated levels of NR4A1 in cancer, it is 
important to determine the regulatory mechanisms behind this expression pattern.  
 
One such mechanism is through microRNAs (miRNAs), which regulate gene 
expression by binding to the 3ʹUTR of target mRNA and effectively inhibit translation 
into protein. Prior to this study, no miRNAs had been identified to directly target NR4A1. 
By using luciferase reporter assays, we identified miR-124, miR-15a, and miR-224 as 
potential NR4A1 regulators. The direct binding of these miRNAs to their potential seed 
regions within the 3ʹUTR of NR4A1 was confirmed by mutagenesis of their respective 
seed sequences. This abrogated the binding and thereby confirmed the direct targeting of 
these miRNAs to these particular sequences. To further study the relationship between 
NR4A1 and these miRNAs, we analyzed endogenous expression levels in several 
pediatric cancer cell lines. NR4A1 was upregulated in RD, Rh41, and Rh30 
rhabdomyosarcoma cells and D341 and Daoy medulloblastoma cells as well as NB3 
neuroblastoma cells. All three miRNAs were downregulated in Daoy cells. Considering 
that miR-124 is highly expressed in the brain and is a tumor suppressor, we decided to 
investigate the functional significance between NR4A1 and miR-124 in Daoy cells. We 
found that miR-124 could decrease NR4A1 mRNA and protein levels as well as the 
expression of several NR4A1 target genes. Overexpression of NR4A1 led to enhanced 
cell viability and proliferation while knockdown resulted in the opposite phenotype. 
Furthermore, stable expression of miR-124 in Daoy cells resulted in decreased 
proliferation and smaller spheroid formation. Lastly, we examined expression levels in 
granule neuron precursors (GNPs), which are the most common cell type in the 
cerebellum where medulloblastoma arises. Interestingly, there was an inverse expression 
pattern in which miR-124 was increased while Nr4a1 was decreased in the differentiated 
GNPs, suggesting a potential role for NR4A1 in neuronal development.   
 
In addition to cancer cell proliferation, the role of NR4A1 in skeletal muscle 
differentiation was also explored. We found that NR4A1 increased during the 
differentiation of human LHCN myoblasts, and that knockdown of NR4A1 impairs 
differentiation and reduces expression of myogenic markers in LHCN as well as SkMC, 
and HSMM primary human skeletal muscle cells. This data agrees with previous studies 
performed in mouse models and mouse C2C12 cells showing increased Nr4a1 expression 
during differentiation as well as the ability of NR4A1 to enhance muscle mass and 
myofiber size.   
 vi 
Together, these two studies highlight two different and opposing functional roles 
of NR4A1 in medulloblastoma and skeletal muscle. The first study identified three 
miRNAs capable of directly targeting and suppressing NR4A1 and also provides a 
rationale for the use of miRNA mimics as a potential therapeutic in cancers with high 
NR4A1 expression. In the second study, we provided evidence that further confirms the 
pro-myogenic function of NR4A1 during skeletal muscle differentiation. It is important 
to understand this basic biology as it can help further understand and treat diseases 
related to muscle such as rhabdomyosarcoma and muscular dystrophy.    
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CHAPTER 1.    INTRODUCTION 
 
 
Nuclear Receptors 
 
 
Discovery and classification 
 
Before the word ‘hormone’ was coined in 1905 by Ernest Starling or the word 
‘receptor’ by Paul Erhlich in 1907, not much was known about hormones or nuclear 
(hormone) receptors [1]. The first NRs cloned were the glucocorticoid and estrogen 
receptors in 1985 and 1986, respectively [2, 3], although the estrogen receptor was 
originally isolated in 1958 by Elwood Jensen [4]. Preceding the discovery of these 
receptors, cortisone, a steroid that binds the glucocorticoid receptor, and thyroxine, an 
iodoamino acid that binds the thyroid receptor, were the first ligands to be isolated and 
analyzed for their structures in 1926 [5, 6]. Soon after in the 1920s and 1930s, the 
pancreatic hormone insulin was characterized along with the steroid hormones estrogen, 
testosterone, and progesterone [1]. It is now known that humans have a total of 48 
nuclear receptors termed the nuclear receptor superfamily, as listed in Table 1-1 [7].  
 
Over the years as more and more NRs were discovered, there was much confusion 
as to the nomenclature of these genes. Hence, in 1999 a group of scientists came together 
to formally name these receptors based on their phylogeny [8]. These 48 nuclear 
receptors have since been classified into 6 subfamilies, with the first subfamily, the 
thyroid hormone receptor-like family, having 8 subgroups. These groupings are based on 
sequence homology [9-11]. There are also several ways of referring to each receptor. 
Other than spelling out the full name of the receptor, it can also be identified by its 
nuclear receptor nomenclature committee (NRNC) symbol, its abbreviation, or its gene 
name. For example, nerve growth factor-induced clone B, a member of the nerve growth 
factor IB-like subgroup, is part of the 4th subgroup and is the first member of its family 
and therefore has the NRNC symbol NR4A1. Its abbreviation is Nur77, although it has 
many other common names including NGFIB, NR4A1, and TR3, and lastly its gene 
symbol is NR4A1.  
 
They can also be grouped into liganded NRs, adopted NRs, and orphan NRs. 
Liganded NRs are those which have a known ligand, such as the estrogen receptor with 
estrogen acting as its ligand. On the other hand, orphan receptors have no known 
endogenous ligand, such as COUP-TF. And as the name implies, adopted receptors are 
those which were once orphans but now have an identified ligand, such as FXR found to 
be activated by bile acids [12]. The initial discovery of nuclear receptors was based on 
using ligands to identify the receptor they bind to, but as technology improved it became 
possible to discover receptors without knowing their ligands, hence the appearance of 
adopted nuclear receptors. 
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Table 1-1. Nuclear receptor superfamily. 
 
Subfamily Group Name Abbreviation Ligand Disease implicated Therapeutic drug name 
Thyroid 
hormone 
receptor-like 
Thyroid hormone 
receptor 
thyroid hormone 
receptor α 
TRα thyroid hormone thyroid resistance 
syndrome, thyroid 
cancer 
evothyroxine, 
levothyroxine, 
liothyronine 
  thyroid hormone 
receptor β 
TRβ thyroid hormone hypercholesterolemia  
 Retinoic acid receptor Retinoic acid receptor α RARα retinoic acids acute promyelocytic 
leukemia, kidney 
disease, Alzheimer's 
disease, skin diseases, 
cancers 
all-trans retinoic acid 
(ATRA) 
  Retinoic acid receptor β RARβ retinoic acids   
  Retinoic acid receptor γ RARγ retinoic acids   
 Peroxisome 
proliferator-activated 
receptor 
Peroxisome 
proliferator-activated 
receptor α 
PPARα Fatty acids and 
prostaglandins 
Type II diabetes, 
atherosclerosis, obesity, 
hyperlipidemia 
fibrates (clofibrate, 
gemfibrozil, fenofibrate) 
  Peroxisome 
proliferator-activated 
receptor β/δ 
PPARβ/δ Fatty acids and 
prostaglandins 
Type II diabetes, 
atherosclerosis, obesity, 
hyperlipidemia  
 
  Peroxisome 
proliferator-activated 
receptor γ 
PPARγ Fatty acids and 
prostaglandins 
Type II diabetes, 
atherosclerosis,  
obesity, hyperlipidemia, 
anaplastic cancer 
thiazolidinediones 
(roziglitazone, 
pioglitazone, 
perflurooctanoic acid), 
RS544  
 Rev-ErbA Reverse-Erb α REV-ERBα heme   
  Reverse-Erb β REV-ERBβ heme   
 RAR-related orphan 
receptor 
RAR-related orphan 
receptor α 
RORα cholesterol and 
ATRA 
atherosclerosis  
  RAR-related orphan 
receptor β 
RORβ cholesterol and 
ATRA 
  
  RAR-related orphan 
receptor γ 
RORγ cholesterol and 
ATRA 
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Table 1-1. Continued. 
 
Subfamily Group Name Abbreviation Ligand Disease implicated Therapeutic drug name 
 Liver X receptor-like Liver X receptor α LXRα oxysterols Alzheimer's disease, 
atherosclerosis, 
dyslipidemia, non-
alcoholic fatty liver 
disease, breast cancer 
TO901317, GW3965, N-
Acylthiadiazolines 
  Liver X receptor β LXRβ oxysterols atherosclerosis, 
dyslipidemia 
 
  Farnesoid X receptor α FXRα oxysterols, bile acids cholestasis, 
hypercholesterolemia, 
biliary cirrhosis, non-
alcoholic fatty liver 
disease 
guggulsterone, 
chenodeoxycholic acid, 
fexaramine 
  Farnesoid X receptor β FXRβ oxysterols   
 Vitamin D receptor-
like 
Vitamin D receptor VDR vitamin D and 
lithocholic acid 
hypocalcemia, 
osteoporosis, renal 
failure, colon cancer, 
diabetic nephropathy, 
hypertension, 
atherosclerosis 
calcitriol, doxercalciferol 
  Pregnane X receptor PXR xenobiotics and 
endobiotics 
cholestatic liver disease, 
hyperbilirubinemia, liver 
injury, cancer 
rifampicin 
  Constitutive androstane 
receptor 
CAR xenobiotics, 
androstane 
cholestatic liver disease, 
type II diabetes 
phenobarbitol 
Retinoid X 
Receptor-like 
Hepatocyte nuclear 
factor-4 
Hepatocyte nuclear 
factor-4 α 
HNF4α fatty acids, palmitic 
acid 
diabetes  
  Hepatocyte nuclear 
factor-4 γ 
HNF4γ fatty acids   
 Retinoid X receptor Retinoid X receptor α RXRα 9-cis retinoic acid 
and docosahexanoic 
acid 
metabolic diseases, 
cancers (skin cancer, 
cutaneous T cell 
lymphoma) 
bexarotene 
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Table 1-1. Continued. 
 
Subfamily Group Name Abbreviation Ligand Disease implicated Therapeutic drug 
name 
  Retinoid X receptor β RXRβ 9-cis retinoic acid and  
docosahexanoic acid 
 
  Retinoid X receptor γ RXRγ 9-cis retinoic acid and  
docosahexanoic acid 
 
 Testicular receptor  Testicular receptor 2 TR2    
  Testicular receptor 4 TR4    
 TLX/PNR Tailless homolog 
orphan receptor 
TLX    
  Photoreceptor cell-
specific nuclear 
receptor 
PNR    
 COUP/EAR Chicken ovalbumin 
upstream promoter-
transcription factor I 
COUP-TFI    
  Chicken ovalbumin 
upstream promoter-
transcription factor II 
COUP-TFII    
  V-erbA-related EAR-2    
Estrogen 
Receptor-like 
Estrogen receptor Estrogen receptor-α ERα estrogens breast cancer, ovarian 
cancer, prostate cancer, 
colon cancer, 
osteoporosis 
tamoxifen, raloxifene, 
gen-estein, 
diethylstilbestrol, 
equineestrogens  
  Estrogen receptor-β ERβ estrogens breast cancer, ovarian 
cancer, prostate cancer, 
colon cancer, 
osteoporosis 
 
 Estrogen related 
receptor 
Estrogen-related 
receptor-α 
ERRα    
  Estrogen-related 
receptor-β 
ERRβ    
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Table 1-1.  Continued. 
 
Subfamily Group Name Abbreviation Ligand Disease implicated Therapeutic drug 
name 
  Estrogen-related 
receptor-γ 
ERRγ    
 3-ketosteroid receptors Glucocorticoid receptor GR glucocorticoids, 
cortisol 
inflammatory diseases 
(Inflammatory bowel 
syndrome, auto immune 
disorder, rheumatoid 
arthritis, gout, asthma, 
cancer) 
dexamethasone, 
cortisol, prednisolone, 
RU486 
  Mineralocorticoid 
receptor 
MR mineralocorticoids 
and glucocorticoids 
(aldosterone) 
heart failure, 
hypertension, 
cardiovascular disease, 
kidney disease 
spironolactone, 
eplerenone 
  Progesterone receptor PR progesterone breast cancer, 
endometriosis 
RU486 
  Androgen receptor AR androgens, 
testosterone 
prostate cancer, 
osteoporosis 
flutamide, bicalutamide 
Nerve 
Growth 
Factor IB-
like 
NGFIB/NURR1/NOR1 Nerve growth factor 
induced gene B 
NGFIB unsaturated fatty 
acids 
  
  Nuclear receptor 
related 1 
NURR1  Parkinson's disease  
  Neuron-derived orphan 
receptor 1 
NOR1    
Steroidogenic 
Factor-like 
SF1/LRH1 Steroidogenic factor 1 SF1 phosphatidylinositols   
  Liver receptor 
homolog-1 
LRH-1 phosphatidylinositols   
Germ Cell 
Nuclear 
Factor-like 
GCNF Germ cell nuclear 
factor 
GCNF    
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Table 1-1.  Continued. 
 
Subfamily Group Name Abbreviation Ligand Disease implicated Therapeutic drug 
name 
Miscellaneous DAX/SHP Dosage-sensitive sex 
reversal, adrenal 
hypoplasia critical 
region, on chromosome 
X, gene 1 
DAX1    
  Small heterodimer 
partner 
SHP  obesity  
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Structure and function 
 
 Structure.  By definition, nuclear receptors are also classified as transcription 
factors, meaning they can bind the promoters of their target genes to modulate gene 
expression. The typical structure of a nuclear receptor consists of a well-conserved DNA-
binding domain (DBD), a moderately-conserved C-terminal ligand binding domain 
(LBD), and a highly variable N-terminal region containing a ligand-independent 
transactivation domain called Activation Function 1(AF-1) as depicted in Figure 1-1A 
[3, 10, 13]. The N-terminal region interacts with coregulatory proteins such as 
coactivators that enhance the transcription of NR target genes [14]. A closer look at the 
DBD reveals two zinc-finger domains as well as the P-box, which is a motif involved in 
DNA-binding specificity as well as dimerization with other nuclear receptors as 
homodimers or heterodimers. In addition to the promoter region, nuclear receptors may 
also bind enhancer and intronic regions of target genes. Nuclear receptors can bind to 
these regions, or more specifically their response elements, either as monomers, 
homodimers, or heterodimers, where heterodimers typically include binding with RXR 
[14]. Orphan receptors typically bind as monomers such as the NR4A family. However, 
there are two nuclear receptors, DAX1 and SHP, that surprisingly do not contain a DBD 
and mainly act as corepressors [15]. There is a flexible hinge region positioned between 
the DBD and LBD that contains the nuclear localization signal (NLS) responsible for 
facilitating the import of the receptor inside of the nucleus. The LBD is the largest 
domain and as its name implies, its function is dependent on the binding of small 
lipophilic ligands in its hydrophobic ligand binding pocket (LBP) [16]. Although the 
structure of the LBD is well conserved, the LBP can greatly vary in size. For example, 
some nuclear receptors such as SF-1 have a large LBP of about 1600 Å3, while some 
orphan receptors completely lack an LBP [15, 17, 18]. For instance, the orphan receptor 
NR4A2 contains bulky hydrophobic amino acid side chains in place of its LBP [18]. In 
addition to the LBP, the LBD also contains a dimerization interface and an additional 
transactivation domain called Activation Function 2 (AF-2), which interacts with and 
recruits coregulators and also contains a second NLS [19]. 
 
Function. Nuclear receptors function to regulate and facilitate a wide variety of 
biological processes including metabolism, reproduction, development, aging, and 
homeostasis [20]. Many of these processes are dependent upon ligands to activate their 
respective nuclear receptors, which in turn act as intermediates to confer signals to 
downstream events [19]. Ligands can include a plethora of signaling molecules such as 
hormones, fatty acids, xenobiotics, cholesterol, vitamin D, steroids, and retinoids [14, 
21]. In the case of orphan receptors, which account for about half of all nuclear receptors, 
these can be induced by many factors such as stress, cytokines, and mitogens [14].  
 
There are three main levels to nuclear receptor function; repression, derepression, 
and transcriptional activation [19]. In the absence of a ligand, nuclear receptor activity is 
suppressed by the binding of a corepressor complex, which typically contains histone 
deacetylase (HDAC) activity. These corepressor complexes commonly contain the 
subunits SMRT/NCoR2 or NCoR1, which directly bind the receptor [14]. Ligand binding 
can occur in either the cytoplasm or the nucleus, and receptors bound by ligands in the   
 8 
 
 
Figure 1-1. The structure and function of liganded and orphan nuclear receptors. 
(A) Typical nuclear receptors consist of a DNA-binding (DBD) and ligand-binding 
domain (LBD) and two transactivation function domains (AF-1 and AF-2) that recruit 
coregulators. (B) Upon activation by various stimuli, nuclear receptors will 
heterodimerize and bind to their target genes in conjunction with recruitment of 
coactivators (SRC-1 and CBP/p300) and release of corepressor (NCoR/SMRT). 
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cytoplasm will translocate to the nucleus [22]. Upon ligand binding, the nuclear receptor 
undergoes a conformational change and derepression occurs in which the corepressor 
complex is replaced with a coactivator complex containing histone acetyltransferase 
(HAT) activity. This HAT activity allows for increased transcriptional activity via 
chromatin decondensation. In the last stage of nuclear receptor function, the coactivator 
complex is replaced by another coactivator complex and the nuclear receptor is now able 
to bind with the promoter of its target gene to induce transcriptional activation of that 
gene via recruitment of transcriptional machinery such as RNA polymerase II as shown 
in Figure 1-1B [14, 15, 23]. More than 350 coactivators have been identified, including 
the more common ones like steroid receptor coactivator 1 (SRC-1), steroid receptor 
coactivator-2 (SRC-2), p300, and cAMP response element-binding protein (CBP) that are 
likely among the first to be recruited by nuclear receptors [14, 15, 24-26]. On the other 
hand, nuclear receptors may mediate repression of target gene expression by recruiting 
corepressors such as the nuclear receptor corepressor (NCoR), silencing mediator for 
retinoid and thyroid hormone receptors (SMRT), and histone deacetylase 3 (HDAC3) 
[27-30]. Nuclear receptors can also mediate gene repression by interacting with other 
transcription factors including activation protein-1 (AP-1) and nuclear factor kappa B 
(NF-kB) [31, 32]. Typically, unliganded nuclear receptors repress their target genes, 
while liganded receptors mediate activation of their target genes. Of course, this is a 
simplistic description of nuclear receptor function. Some nuclear receptors such as 
orphan receptors may not follow these steps since they may or may not be activated by a 
ligand [19]. Instead, they may be constitutively active such as the orphan nuclear receptor 
NR4A1 [33]. 
 
In addition to their transcriptional activity, nuclear receptors can also interact with 
other signaling pathways to impose negative or positive effects on their downstream 
signaling. Their activity and function can also be affected by post-translational 
modifications such as phosphorylation, acetylation, methylation, sumoylation, and 
ubiquitination [15, 34-37]. These interactions can also be dependent on the cell and tissue 
type.    
 
 
Role in cancer 
 
Nuclear receptors are molecular targets for approximately 13% of FDA-approved 
drugs [38], and inhibiting this receptor signaling has proved to be beneficial in treating 
cancer. Since nuclear receptors play a variety of vital roles, disruption or deregulation of 
their functions can lead to serious consequences. However, their ability to bind ligands 
makes them therapeutic targets in certain diseases and cancers. Agonists (molecules that 
enhance receptor function) and antagonists (molecules that disrupt or inhibit receptor 
function) can play important roles in drug discovery. Certain compounds with 
agonist/antagonist properties are classified as selective nuclear receptor modulators 
(SNuRMs), which act as ligands but differ in their activities from the natural endogenous 
ligands [15, 20]. More specifically, there are classes of compounds for certain receptors 
such as selective estrogen receptor modulators (SERMs) for ER, selective androgen 
receptor modulators for AR, and selective peroxisome proliferator-activated receptor 
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modulators for PPAR [39]. The more common nuclear receptors targeted in cancer 
therapy are the estrogen receptor (ER) in breast cancer, the androgen receptor (AR) in 
prostate cancer, the retinoic acid receptor (RAR) in acute promyelocytic leukemia [15], 
and the vitamin D receptor in breast and colon cancer.   
 
In ER-positive breast cancer, estrogen signaling has been found to promote tumor 
growth and cancer progression, and treatment with SERMs is used to block this 
signaling. These modulators function by affecting the recruitment of certain coactivators 
and corepressors in a tissue-dependent manner [40-42]. For example, the SERMs 
tamoxifen and raloxifene increase corepressor recruitment in mammary cells, resulting in 
inhibition of estrogen signaling and decreased breast cancer growth. On the other hand, 
tamoxifen acts as an agonist in endometrial cells and mediates coactivator recruitment, 
leading to a higher risk of endometrial cancer [43]. However, raloxifene does not have 
this agonistic effect in endometrial cells. This is most likely due to preferential binding of 
coregulators to the AF-1 domain depending on certain factors such as tissue and cell type 
[44-48]. SERMs can also act as agonists in other tissues including bone, uterine, and 
cardiovascular tissue [49, 50]. This kind of tissue selectivity can be beneficial since 
estrogen signaling can be inhibited in breast cancer while still allowing for normal 
function in other tissues. This can also be useful in the case of osteoporosis in which 
raloxifene exerts protective effects while avoiding the increased risk of endometrial 
cancer that could result from tamoxifen treatment in menopausal women [20, 51]. 
 
Another major nuclear receptor being targeted in disease is the glucocorticoid 
receptor (GR) by dexamethasone and prednisolone in inflammatory diseases such as 
rheumatoid arthritis, immunological disorders, and cancer [20]. These synthetic ligands 
function as agonists of GR and enhance its ability to disrupt NF-kB and AP-1 activities, 
leading to decreased proinflammatory cytokines and tumor necrosis factor-α, and 
ultimately resulting in reduced inflammation [52-54]. However, continued treatment with 
dexamethasone and prednisolone can lead to serious side-effects including diabetes and 
osteoporosis [55]. 
 
Additional receptor targets include PPARα by fibrates (clofibrate, gemfibrozil, 
fenofibrate) in hyperlipidemia, PPARγ by thiazolidinediones (roziglitazone, pioglitazone, 
perflurooctanoic acid) in type II diabetes, RXR by bexarotene and alitretinoin in cancer, 
RAR by all-trans retinoic acid (ATRA) in acute promyelocytic leukemia, and AR by 
flutamide and bicalutamide in prostate cancer [15, 56-60]. The xenobiotic receptors CAR 
and PXR can also play a role in cancer by mediating the metabolism of cancer drugs and 
drug resistance. PXR is commonly used in the pharmaceutical industry to identify 
dangerous drug-drug interactions when screening for new cancer therapies [61]. 
Furthermore, agonists of PXR have therapeutic potential in treating cholestatic liver 
disease and preventing hyperbilirubinemia [22, 62]. Future drug targets include FXR in 
nonalcoholic steatohepatitis and cholestatic liver disease and LXR in atherosclerosis and 
Alzheimer’s disease by using agonists of these receptors [30, 61, 63]. Many other nuclear 
receptors are therapeutic targets in various diseases as listed in Table 1-1 [59, 64, 65]. 
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NR4A Family 
 
 
Discovery 
 
The NR4A family consists of NR4A1 (Nur77, NGFI-B, TR3), NR4A2 (Nurr1), 
and NR4A3 (Nor-1). They were first characterized as immediate-early response genes 
induced by nerve growth factor in PC12 cells [66, 67]. NR4A1 was first isolated in 1989 
by Chang et al. from human prostate in which they found that NR4A1 was a 64 kDA 
receptor protein that could bind to DNA [68]. This was following the discovery of Nr4a1 
in the mouse since Chang et al. noted that human NR4A1 had 86% nucleotide and 91% 
amino acid sequence homology to mouse Nr4a1 [68]. Shortly thereafter, Nr4a2 was 
identified and cloned from a mouse brain cDNA library by Law et al. and subsequently 
from fetal human tissue [69-72]. Nr4a2 was found to be highly expressed in the brain 
compared to other tissues, suggesting an important role for NR4A2 in the central nervous 
system [69]. Lastly, Nr4a3 was first identified in forebrain neuronal cells that were 
undergoing apoptosis. NR4A3 appropriately stands for neuron derived orphan receptor 
and was found to encode a 68 kDa protein [73].   
 
 
Structure and function 
 
Structure. As mentioned, the NR4A family has been classified as orphan 
receptors due to the lack of endogenous ligands. However, a recent report claims they are 
no longer orphans since there are both synthetic and natural compounds that have been 
shown to bind the LBD of all three NR4As [74]. Additionally, unsaturated fatty acids 
(UFAs) have been found to act as natural endogenous ligands by binding to the LBD of 
NR4A1 and NR4A2 [75, 76]. Interestingly, the LBDs of NR4A1 and NR4A3 contain 
hydrophilic surfaces as opposed to the hydrophobic LBP of liganded nuclear receptors 
[77, 78]. In addition, the LBDs of the NR4A family completely lack an LBP and classical 
coactivator binding site and instead have bulky hydrophobic side chains in place of an 
LBP where agonists would normally bind [18, 79]. For this reason, it was believed there 
could be no ligand for the NR4As, though this theory has been disproven by the 
discovery of small-molecule NR4A1 agonists [75]. Since NRs commonly undergo 
conformational changes upon ligand binding, it is possible that the NR4As reveal a 
binding pocket in response to ligand interactions. This was proven to be true for NR4A1 
in which the UFA arachidonic acid induced a conformational change, allowing it to bind 
to the LBD of NR4A1 [75]. In addition, arachidonic acid was found to preferentially bind 
to NR4A1 oligomers as opposed to monomers and appeared to stabilize these oligomers 
[75]. 
 
In terms of sequence homology between the NR4A members, their DBDs and 
LBDs are well conserved with about 91-95% homology in the DBD and about 60% in the 
LBD, however the N-terminal containing the AF-1 domain is highly divergent [70, 80, 
81]. This higher level of variation within the AF-1 domain likely recruits different 
cofactors for each NR4A in response to stimuli, which may explain the differential 
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binding of the NR4As to their target gene promoters, thereby resulting in the unique 
responses and functions of each NR4A receptor. More specifically, cofactors have been 
shown to bind NR4A1 protein between helices 11 and 12 in a hydrophobic region [33, 
82, 83]. In terms of the NR4A1 gene structure, it is known to have seven exons, with the 
AF-1 domain in exon 2, the DBD in exons 3 and 4, and the LBD in exons 5 to 7 [70]. The 
recruitment of coregulators has been shown to involve the AF-1 domain to mediate 
NR4A-dependent transcription [33, 77, 78, 84, 85]. 
 
Function. Like all nuclear receptors, the NR4As function as transcription factors 
and bind the promoters of their target genes to modulate their expression in response to 
certain stimuli. Previously characterized as orphans, it was thought that they act 
independently of ligands to constitutively modulate gene expression [33, 81, 86-88], 
however this may no longer be the case since ligands such as UFAs have been discovered 
to bind the LBD of NR4A1 [75]. They can bind as monomers, homodimers, or 
heterodimers with each other or with RXR [81, 89-92]. The specific sequence they bind 
as monomers is called the NGFI-B response element (NBRE) and consists of 5’-
A/TAAAGGTCA [93-95]. However as homodimers and NR4A heterodimers, they bind 
the Nur-responsive element (NurRE), which consists of a sequence motif found naturally 
occurring in the pro-opiomelanocortin (POMC) promoter [90]. Of the NR4A family, only 
NR4A1 and NR4A2 form heterodimers with RXR, which bind to the retinoic acid 
response element DR5 to mediate the function of RXR in retinoid signaling [91, 92]. 
 
The NR4A family is classified as immediate early response genes and can be 
induced by a wide variety of physiological signaling molecules to mediate their functions 
in proliferation, metabolism, inflammation, differentiation, apoptosis, survival, and DNA 
repair, among other functions [33, 96, 97]. They have an innate ability to respond quickly 
to these various stimuli, which include growth factors, stress, fatty acids, hormones, 
cytokines, neurotransmitters, prostaglandins, phorbol esters, calcium, and various 
apoptotic signals [33, 98-109]. In addition, they can also be induced by membrane 
depolarization, magnetic fields, and mechanical stress [33, 104, 110-112]. Importantly, 
the effects of the NR4A family are extremely context dependent and can vary depending 
on the specific tissue and cell type as well as experimental conditions. Moreover, their 
functions are heavily influenced by their expression levels, subcellular localization, 
posttranslational modifications, interactions with other transcription factors, and crosstalk 
with many signaling pathways [97]. 
 
 
Physiological roles 
 
Main functions. The NR4A family is expressed in a variety of tissues, mainly in 
those that require higher levels of metabolism and energy. These include skeletal muscle, 
adipose, kidney, liver, T-cells, heart, and the brain [33, 92, 113-116]. The first major 
function identified for NR4A1 was its requirement for T-cell receptor (TCR)-mediated 
apoptosis in immature thymocytes and T-cell hybridomas [117, 118]. Both NR4A1 and 
NR4A3 are highly expressed during TCR-mediated cell death [117, 118], and inhibiting 
NR4A1 effectively blocks apoptosis in T-cell hybridomas. The lack of NR4A1 in 
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transgenic mice can also prevent the process of negative selection [119, 120]. In contrast, 
the presence of wild type Nr4a1 or Nr4a3 in mice enable cell death in thymocytes, 
resulting in reduced numbers of thymocytes and mature T cells [119-121]. A proposed 
mechanism by which NR4A1 mediates this process is via transcriptional activation of 
pro-apoptotic genes including Fas-ligand (FasL) [122]. In addition, both NR4A1 and 
NR4A3 may localize to the mitochondria and interact with Bcl-2 to induce apoptosis 
during the negative selection of T cells [97, 123]. Furthermore, calcium signaling was 
also found to be required for NR4A1-mediated apoptosis in T cells [124]. 
 
Compared to NR4A1, not as much is known about the physiological functions of 
NR4A2 and NR4A3. However, it is known that NR4A2 plays an important role in the 
synthesis of dopamine by mediating the transcriptional activation of tyrosine 
hydroxylase, an enzyme essential for dopamine synthesis [125]. Furthermore, NR4A2 is 
crucial to the normal development of the midbrain by ensuring the proper synthesis of 
dopaminergic neurons and facilitating neurotransmitter identity [126]. Interestingly, 
NR4A2 has been implicated in Parkinson’s disease due to genetic mutations [127]. 
 
Neurological functions. In addition to the role of NR4A2 in dopamine synthesis, 
the NR4As appear to have neuroprotective functions as well as roles in learning as they 
are induced in the hippocampus during fear conditioning in mice [128]. In addition, 
NR4A1 was found to be required for object location while NR4A2 was important for 
recognition, long term memory, and object location [129]. NR4A1 has also been 
implicated in synaptic remodeling as well as a disease resulting from antipsychotic drugs 
[74, 130, 131]. Furthermore, exogenous NR4A1 expression can mediate the repair of 
damaged neurons after stroke wherein NR4A1 is normally decreased in neural cells 
lacking oxygen and glucose [132]. 
 
Inflammation and metabolism. The NR4A family has been found to play roles 
in steroidogenesis by regulating the expression of genes involved in the hypothalamic-
pituitary-adrenal (HPA) axis, a complex network of glands important for many bodily 
functions including digestion, mood, and the immune system [133-135]. For example, 
corticotropin releasing hormone (CRH) and POMC expression are enhanced by NR4A1, 
resulting in activation of the HPA axis and downstream adrenal glucocorticoid synthesis 
[135]. The NR4As may also have roles in muscle, adipose, and macrophages as they are 
induced by various stimuli in these tissues. For example, all three NR4A receptors are 
rapidly induced by lipopolysaccharide (LPS) and more slowly induced by IFNγ in 
macrophages while only NR4A1 expression is enhanced by oxidized lipids and cytokines 
in these cells [136, 137]. Although NR4A1 is induced by inflammatory stimuli, it appears 
to play a protective role during inflammation as demonstrated by its involvement in T-
cell development, Treg cell differentiation, and its anti-inflammatory effects in 
macrophages [138-140]. 
 
The NR4As are also induced in skeletal muscle during recovery from intense 
exercise [141]. NR4A1 is important for energy expenditure since knockdown of NR4A1 
in C2C12 skeletal muscle cells resulted in decreased expression of genes involved in 
lipolysis and lipid homeostasis [142], suggesting a role for NR4A1 in treating obesity. 
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Similarly, the NR4As are induced during the differentiation of adipocytes, however their 
expression does not appear to be a requirement for differentiation to occur [96, 143]. 
These studies indicate that the NR4A family is important in regulating lipid and glucose 
metabolism, implicating them in the treatment of metabolism disorders.  
 
Furthermore, the NR4A family was found to be upregulated in the livers of type I 
and type II diabetic mice [144, 145]. Knockout of NR4A1 in the liver of type II diabetic 
mice brought the elevated levels of glucose back to almost normal levels and also 
resulted in decreased expression of gluconeogenic genes [144, 145]. Consistent with this 
finding, overexpression of NR4A1 induced genes involved in gluconeogenesis and 
enhanced hepatic glucose production in mice [96]. NR4A1 overexpression can also 
increase LDL cholesterol and decrease HDL cholesterol while reducing triglyceride 
levels in the liver [146]. Other studies have shown that NR4A1-deficient mice develop 
insulin resistance in their skeletal muscle when fed a high-fat diet [147]. These mice also 
have decreased gene expression related to glucose utilization in skeletal muscle, whereas 
NR4A1 overexpression in C2C12 cells results in increased expression of genes involved 
in glucose and glycogen metabolism [147, 148]. This indicates a role for the NR4A 
family in the promotion of type II diabetes. 
 
Cardiovascular system. In addition, the NR4As play roles in energy homeostasis 
and the vascular system. All three NR4As had increased expression in brown adipose 
tissue (BAT) during cold exposure, and NR4A1 is induced after β-adrenergic stimulation 
in brown adipocytes, although Nr4a1 deficient mice do not display abnormal 
nonshivering thermogenesis [149]. This lack of NR4A1 may be compensated by the 
potential redundancy of NR4A3 since NR4A3 is also induced in brown fat during cold 
exposure [149]. Interestingly, tissue-specific knockdown of Nr4a3 in the third cerebral 
ventricle in mice resulted in decreased food consumption and body weight, suggesting a 
role for the NR4As in energy homeostasis by affecting food intake [96]. In terms of the 
vascular system, the NR4As are expressed in atherosclerotic lesions and have been 
shown to regulate genes involved in vascular remodeling processes such as proliferation 
and inflammation [96]. NR4A1 appears to play a protective role in cardiovascular disease 
since mice fed a high fat diet experienced decreases in atherosclerotic plaque formation, 
inflammation, and hepatic lipid deposition in response to NR4A1 overexpression [150-
152]. In contrast, Nr4a3 knockdown in mice decreases hypercholesterolemia-induced 
atherosclerosis, suggesting that NR4A3 may promote atherosclerosis [153]. 
 
NR4A knockout mice. Surprisingly, NR4A1-null mice do not display abnormal 
thymic and peripheral T cell death [133, 154]. Overall, they appear healthy with no 
noticeable phenotype or developmental problems [154]. The hypothalamic and pituitary 
systems also appear to function normally, as well as steroidogenesis [33, 133]. One 
explanation is the possible functional redundancy between the NR4A family wherein the 
other members may compensate for the lack of NR4A1. For example, it is known that 
NR4A3 is also capable of pro-apoptotic activity in thymocytes, and NR4A2 and NR4A3 
also play roles in the HPA axis that could regulate HPA-related genes in place of NR4A1 
[33, 123, 134, 135, 154, 155]. However, mice with both Nr4a1 and Nr4a3 knocked out 
quickly develop acute myeloid leukemia (AML) and die within 2 to 4 weeks postnatally 
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[156]. As a result of this double knockout, there was increased accumulation of 
hematopoietic stem cells. Expression of NR4A1 and NR4A3 was also found to be 
decreased in patients with AML [156]. 
 
Interestingly, mice that lack Nr4a2 develop to full-term but die at birth, seemingly 
due a defect in respiratory function. However, others report it is due to the lack of 
dopaminergic neurons in the midbrain with the observation of abnormal movements such 
as difficulty turning when the mice were placed on their backs as well as the inability to 
suckle [126, 157, 158]. Finally, Nr4a3 knockout mice exhibit inner ear defects with 
impaired bi-directional circling behavior, which was associated with decreased 
endolymphatic fluid space in the ear canals [159, 160]. In addition, Nr4a3-null mice are 
more susceptible to limbic seizure activity due to excitotoxic glutamate receptor agonists 
[160]. In contrast, another study found that mice lacking Nr4a3 die around embryonic 
day 8.5 (E8.5) due to incomplete gastrulation [161].  
 
 
Apoptotic function 
 
Of interest is the translocation function of NR4A1 from the nucleus to the 
mitochondria to induce apoptosis. Although it appears the main function of NR4A1 is to 
exert pro-oncogenic and anti-apoptotic effects in cancer cell lines, there are several 
instances in which this is not the case. For example in lung and other cancer cell lines, 
addition of the retinoid CD437 (AHPN) induces apoptosis in a NR4A1-dependent 
manner (Figure 1-2) [162-170]. Many other stimuli have also been shown to induce 
nuclear export of NR4A1 to mediate apoptosis, including 5-fluorouracil, viruses, phorbol 
ester (TPA), butyrate, cadmium, and cytosporone B (Csn-B), among many others listed in 
Table 1-2 [67]. These pro-apoptotic compounds may act by either inducing NR4A1 
expression or by directly binding to NR4A1. For example, one study shows that the 
natural product Csn-B (derived from endophytic fungi) is able to directly interact with the 
LBD of NR4A1 to mediate NR4A1-dependent apoptosis through multiple mechanisms, 
including both transcription-dependent and -independent functions (Figure 1-2) [171, 
172]. Csn-B treatment of gastric cancer cells resulted in enhanced NR4A1 expression, 
which was due in part to autoregulation in which NR4A1 was able to bind its own 
promoter to induce expression [171]. NR4A1 was also found to transcriptionally decrease 
the antiapoptotic protein BRE in response to Csn-B [172-174]. On the other hand, Csn-B 
induced translocation of NR4A1 to the mitochondria prior to activation of the apoptotic 
cascade [171]. This was the first evidence of a molecule that could act as a ligand to bind 
and activate NR4A1. 
 
The mechanism by which NR4A1 mediates apoptosis involves directly binding to 
the anti-apoptotic protein Bcl-2 at the mitochondria and converting it to a pro-apoptotic 
protein. This conversion involves a conformational change of Bcl-2 that reveals its pro-
apoptotic BH3 (Bcl-2 homology) domain [175]. Subsequently, cytochrome c is released 
and the intrinsic apoptotic cascade is evoked [168]. In addition to the mitochondria, 
NR4A1 may also localize to the endoplasmic reticulum (ER) to mediate apoptosis. 
Treatment of neuroblastoma cells with retinoid-related compound CD437 (AHPN)   
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Figure 1-2. NR4A1 is induced by cytotoxic agents to mediate cell death. 
NR4A1 can induce apoptosis in response to apoptotic compounds by either translocating 
to the mitochondria or to the endoplasmic reticulum and converts Bcl-2 to a proapoptotic 
protein. NR4A1 can also mediate apoptosis by transcriptionally activating genes involved 
in the cell death program. 
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Table 1-2. Compounds and apoptotic stimuli that induce Nur77 to mediate cell 
death, mainly through mitochondrial localization. 
 
Inducer Model system References 
N-butylidenephthalide (BP) HCC [176] 
di-n-butyltin dichloride (DBTC) and tri-n-butyltin 
chloride (TBTC) 
Rat thymocytes [177] 
Synthetic chenodeoxycholic acid derivatives Gastric cancer  [178] 
Cisplatin Ovarian cancer [179] 
Butyrate  Colon cancer  [180] 
Sulindac  Colon cancer  [180] 
5-fluorouracil  Colon cancer  [180] 
Phorbol ester 12- O-tetradecanoyl phorbol-13-acetate 
(TPA) 
Prostate and gastric cancer [168, 181]  
Calcium ionophore A23187 Prostate cancer cells [168] 
Etoposide VP-16 Prostate and gastric cancer [168, 181]  
AHPN analog 6-[3-(1-adamantyl)-4- hydroxyphenyl]-3-
chloro-2-naphthalenecarboxylic acid (MM11453) 
Prostate cancer  [168] 
Retinoid (Z)-4- [2-bromo-3-(5,6,7,8-tetrahydro-
3,5,5,8,8- pentamethyl-2-
naphthalenyl)propenoyl]benzoic acid (MM11384) 
Prostate cancer  [168] 
Sindbis virus  Primary B cells [182] 
Insulin-like growth factor-binding protein-3 (IGFBP-3) Prostate cancer  [183] 
Shikonin derivatives Lung and cervical cancer [184] 
Cytosporone B (Csn-B) and related analogues Gastric cancer  [171, 173]  
9-cis-retinoic acid Gastric cancer  [170] 
Cadmium Lung cancer  [185] 
CD437 (AHPN) Neuroblastoma and 
esophageal squamous 
carcinoma 
[186] 
C-DIMs Pancreatic cancer [187, 188] 
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induced NR4A1 nuclear export and interaction with Bcl-2 at the ER. This interaction led 
to Ca2+ release from the ER and subsequent ER stress, resulting in apoptosis via ER-
mediated caspase-4 activation and ultimately activation of caspase-9 [186]. 
 
This apoptotic function of NR4A1 is currently being exploited for its therapeutic 
potential in cancer. One class of compounds called methylene-substituted 
diindolylmethanes (C-DIMs) looks especially promising as one group in particular has 
been studying the utilization of C-DIMs in treating cancer via NR4A1-mediated 
apoptosis [67]. C-DIMs are small lipophilic molecules synthetically derived from 
cruciferous vegetables and have been found to inhibit cell and tumor growth in many 
types of cancers both in vitro and in vivo [65, 170]. One C-DIM in particular, DIM-C-
pPhOCH3, induces apoptosis in several cancer types, and knockdown of NR4A1 inhibits 
this effect in pancreatic, colon, and bladder cancer cells [187, 188]. Several pro-apoptotic 
genes including TRAIL, FasL, and p21 were also induced, whereas NR4A1 knockdown 
abrogated this effect [67]. Interestingly, NR4A1 was not exported from the nucleus and 
did not translocate to the mitochondria during C-DIM-induced apoptosis, suggesting 
NR4A1 mediates apoptosis via transcriptional activation of these pro-apoptotic genes  
(Figure 1-2) [67]. 
 
On the other hand, the C-DIM analog DIM-C-pPhOH does not activate NR4A1. 
Instead, it induces apoptosis by preventing NR4A1 from transcriptionally activating anti-
apoptotic genes such as survivin [67, 187]. Thus, C-DIMs exhibit anti-tumor properties 
by acting as both activators and deactivators of NR4A1 and take advantage of the 
differential activation of target genes dependent on the specific stimuli [67]. It is also 
possible to synthesize NR4A1 mimics. For example, one group has created a nanopeptide 
called NuBCP-9 (NR4A1-derived Bcl-2-converting peptide with 9 amino acids), which is 
capable of inducing apoptosis in cancer models in vitro and in vivo by replicating the 
action of NR4A1 and converting Bcl-2 to a pro-apoptotic molecule [189]. This NR4A1 
mimic would be beneficial in the treatment of breast cancer since this cancer type has 
higher Bcl-2 expression [172]. Furthermore, the anticancer drug paclitaxel was found to 
mimic the effects of NR4A1 on Bcl-2 [190]. In all, many anti-tumorigenic compounds 
can induce NR4A1-mediated apoptosis through various mechanisms including the 
induction of NR4A1 expression and subsequent mitochondrial or ER targeting (CD437 
and TPA), direct binding of compounds (Csn-B) with NR4A1 to activate apoptosis via 
genomic and non-genomic functions, and either activating or deactivating NR4A1 
transcriptional activity (C-DIMs). 
 
 
MicroRNAs 
 
 
Discovery and nomenclature  
 
Discovery. The first miRNA discovered was lin-4 in Caenorhabditis elegans (C. 
elegans) in 1993 [191]. Seven years passed before the second miRNA (let-7) was 
identified in 2000, also in C. elegans [192, 193]. Initially, it was thought that miRNAs 
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were specific to C. elegans until additional miRNAs were discovered in several other 
organisms, including humans [194, 195]. To catalog of all the miRNAs identified, a 
database called miRBase was created, with the most recent update released in 2014 
(miRBase 21). This miRNA registry now contains 28,645 hairpin precursor miRNAs, 
which represents 35,828 mature miRNAs across 223 species (miRBase 21). Of these 
miRNAs, 1,881 precursors and 2,588 mature miRNAs belong to humans.  
 
Nomenclature. For every miRNA identified, each is assigned a number 
corresponding to the order in which it was discovered. To specify the organism that the 
miRNA pertains to, three letters are added before the ‘miR’, such as hsa-miR-124 for 
Homo sapiens and mmu-miR-124 for Mus musculus. To denote the mature form of the 
miRNA, the ‘r’ is capitalized (miR-124), whereas a lower case ‘r’ (mir-124) indicates 
both the gene and precursor forms. When mature miRNAs have identical sequences but 
are processed from different precursor miRNAs, they are differentiated by adding a 
number to the end of their name, such as miR-124-1 and miR-124-2. Conversely, mature 
miRNA sequences that differ by one or two nucleotides are denoted by a letter, such as 
miR-34a and miR-34b. In addition, miRNAs are processed from precursor miRNAs into 
two complementary mature miRNAs where one is on the 3ʹ strand and the other resides 
on the 5ʹ strand. These can be denoted by adding ‘3p’ or ‘5p’, such as miR-124-3p and 
miR-124-5p. One version may be predominantly expressed over the other, and when the 
dominant version is known, it keeps the common name (miR-124), whereas the less 
dominant one is indicated with an asterisk (miR-124*) [196-199]. 
 
 
Biogenesis and function   
 
miRNAs are non-coding RNAs consisting of 18 to 23 nucleotides that regulate 
gene expression by binding to the 3ʹ untranslated region (3ʹUTR) of their target gene and 
degrading the mRNA, thereby preventing its translation into protein [200, 201]. About 
half of all miRNAs reside in non-protein coding genes, while the other half are usually 
within the introns of protein coding transcripts [202]. RNA polymerase II transcribes 
them into long primary miRNAs (pri-miRNA) that resemble a stem-loop structure, which 
are then cleaved by the enzyme Drosha before becoming precursor miRNA (pre-miRNA) 
[203]. These pre-miRNAs are then exported into the cytoplasm via exportin-5 in a 
RanGTP-dependent fashion where they are further cleaved by Dicer into mature 
miRNAs, as shown in Figure 1-3 [204-206]. During the final stage of biogenesis, the 
mature miRNAs consist of two complementary strands that are separated with the more 
stable passenger strand being degraded and the unstable guide strand being incorporated 
into the RNAi induced silencing complex (RISC) [195, 207, 208]. This complex is then 
able to bind the 3ʹUTR of its target mRNA in the seed region, which consists of 6 to 8 
complementary nucleotides. Although the 3ʹUTR is the main target site, miRNAs may 
also bind the 5ʹUTR as well as the coding sequence [209, 210].  
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Figure 1-3. miRNA biogenesis and function. 
miRNAs are transcribed by RNA polymerase II (Pol II) into either polycistronic or 
monocistronic pri-miRNA, which are cleaved by Drosha into pre-miRNA. Exportin-5 
mediates the translocation of pre-miRNA into the cytoplasm where it is cleaved by Dicer 
into mature miRNA. A single strand of the mature miRNA is incorporated into the RISC 
complex, which can then bind to the 3’UTR of target genes to mediate gene suppression. 
This can lead to inhibition of NR4A oncogenic functions such as proliferation, survival, 
chemoresistance, and migration. 
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Therapeutic potential  
 
miRNAs are important regulators of almost every cellular process and are 
estimated to regulate 60% of the human genome [211]. They are able to form intricate 
networks wherein a single miRNA can target hundreds of genes, while a single gene may 
be targeted by numerous miRNAs. This complex regulation has the potential to have 
profound effects on biological processes. For example, miRNAs have been shown to play 
important roles in cancer where they can act as tumor suppressors by targeting oncogenes 
or as oncomiRs by targeting tumor suppressors [212, 213]. Furthermore, many cancers 
exhibit aberrant miRNA expression where the tumor suppressor-like miRNAs are 
downregulated, most likely due to hypermethylation of the promoter [214].  
 
In addition to miRNAs acting as biomarkers, they have also seen increased 
potential for use as therapeutic agents such as miRNA replacement therapy using miRNA 
mimics [215]. For instance, the miR-34 family harbors strong inhibitory effects on tumor 
growth in a variety of cancers. It exerts these effects through a number of mechanisms 
including the direct suppression of mitogenic genes (cyclin E2, E2F3, and CDK4) as well 
as the anti-apoptotic gene SIRT1, allowing for increased expression of the apoptotic 
genes p53, p21, and PUMA [216]. In addition, p53 induces miR-34 expression, resulting 
in a positive feedback loop [217, 218]. A cancer therapy utilizing the power of miR-34 is 
currently being tested where a miR-34 mimic is encapsulated in a liposome to allow for 
more targeted delivery in a range of cancers and is currently being tested in phase I 
clinical trials. This is the first miRNA to enter clinical trials, and the results thus far 
appear promising [219]. Many other tumor suppressor-like miRNAs exist with similar 
effects to miR-34, suggesting the potential for further exploration of miRNA replacement 
therapy if the miR-34 mimic proves successful.    
 
On the other hand, miRNAs may play an oncogenic role such as the miR-17-92 
cluster promoting tumorigenesis in a wide range of cancers [220]. In addition to cancer, 
miRNAs can have important functions in metabolic disorders, autoimmune diseases, 
genetic diseases, and infectious diseases [195]. Of importance, the viral replication of 
hepatitis C virus (HCV) was found to be dependent on miR-122 [221]. In order to block 
miR-122 function, a drug was developed (SPC3649) to effectively bind the miRNA in a 
locked nucleic acid fashion. After successful experimentation in chimpanzees, the drug is 
currently being tested in phase II clinical trials in humans [222]. If successful, this will be 
the first miRNA-based therapy for HCV [195].     
 
 
Hypothesis and Specific Aims 
  
Studies have shown that NR4A1 is upregulated in many solid tumors, and this 
overexpression can lead to increased cell proliferation in cancer cell lines, indicating an 
oncogenic role for this nuclear receptor. Our overall hypothesis is that miRNAs can 
regulate the expression and downstream function of NR4A1, as depicted in Figure 1-3. 
We theorize that one of the causes for upregulation of NR4A1 in cancer is due to 
downregulation of tumor suppressor-like miRNA regulators of NR4A1.  
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In addition to this first project, we decided to explore the potential function of 
NR4A1 during the differentiation of skeletal muscle. Previous studies found that NR4A1 
expression increases during skeletal muscle differentiation. Thus, we hypothesize that 
NR4A1 is playing a pro-myogenic role during this process. To investigate these 
hypotheses, we proposed the following aims: 
 
1.  Elucidate the miRNAs that are directly regulating NR4A1 and their effects on the 
proliferative function of NR4A1 in pediatric cancer cell lines.  
 
2.  Determine the importance of NR4A1 in skeletal muscle differentiation. 
 
 
Significance of Study 
 
NR4A1 has been mainly studied in adult cancers, with little research on its role in 
pediatric cancers. Although we propose to focus on pediatric cancer types, this novel 
study of the interaction between miRNAs and NR4A1 could have therapeutic potential in 
both adult and pediatric cancers. NR4A1 is an ideal candidate for a therapeutic target and 
a potential biomarker in cancer. On the other hand, miRNAs can act as tumor suppressors 
and are useful as prognostic markers as well as miRNA mimic therapy to treat a variety 
of cancers.   
 
The discovery of miRNAs that target NR4A1 will add a new aspect to NR4A1 
regulation. This study could demonstrate clinical translation through the use of in vivo 
models in which miRNAs are used as therapy for the pediatric tumors in which NR4A1 is 
aberrantly amplified. The majority of published research on NR4A1 as a therapeutic 
target involves utilizing agonists to induce NR4A1-mediated apoptosis, but none have 
delved into using miRNAs to influence NR4A1 expression and genomic actions.  
 
In addition, our initial studies show that differentiation of skeletal muscle cells is 
severely delayed upon knockdown of NR4A1. This data supports previous studies 
showing the importance of NR4A1 in the muscle mass of mice. This information could 
be useful in terms of cancer therapy since malignancies such as rhabdomyosarcoma 
(RMS) form as a result of cells failing to differentiate. Furthermore, muscle-related 
diseases can arise such as muscular dystrophy, a disease that is prevalent in younger 
populations and is characterized by loss of muscle mass and progressive weakness. 
Determining the role of NR4A1 during skeletal muscle differentiation may help 
understand the formation of RMS as well as diseases related to muscle.   
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CHAPTER 2.    THE REGULATORY EFFECTS OF MICRORNAS ON NR4A1 IN 
CANCER 
 
 
Introduction 
 
NR4A1, a member of the NR4A family of nuclear receptors, is known for its 
oncogenic effects in cancer cells. These effects are heavily dependent on its role as a 
transcription factor to promote expression of genes leading to cell proliferation and 
survival. The expression and function of NR4A1 are regulated by post-translational 
modifications and protein-protein interactions, as well as transcriptional regulation by 
other transcription factors. NR4A1 is aberrantly expressed in many cancers, and one way 
to therapeutically modulate its expression is through microRNA (miRNA) replacement 
therapy.  This chapter will explore the ways in which miRNAs may be affecting NR4A1 
expression and function in the context of cancer. The role of NR4A1 in cancer will first 
be discussed, followed by the many different ways it may be regulated by miRNAs. Both 
direct and indirect effects will be detailed since there are not many miRNAs shown to 
target NR4A1 directly. miRNAs may be targeting NR4A1 indirectly by preventing the 
expression of genes that would normally interact and regulate NR4A1 via transcriptional 
regulation, post-translational modifications, and protein-protein interactions. These 
regulatory networks will be related back to cancer and hypothetical situations will be 
discussed on how they may affect tumor formation and progression. It is important to 
understand these networks in order to determine the best possible way for treating 
cancers in which NR4A1 is aberrantly expressed and plays oncogenic roles.  
 
 
NR4A1 in Cancer 
 
In many adult cancers, NR4A1 is overexpressed and appears to play a 
proliferative role. Bladder [223, 224], breast [187, 225-228], colon [180, 188, 228-231], 
liver [176, 231, 232], pancreatic [233, 234], prostate [235], ovarian [228, 236], and lung 
[167, 228, 237, 238] cancer all display increased NR4A1 compared to their normal 
counterparts, with melanoma [228] expressing the highest levels of NR4A1. The 
transactivation and DNA-binding domains of NR4A1 appear to be the culprit for its 
proliferative function in these cancers. Through transcriptional upregulation of genes 
involved in cell cycle progression and inhibition of apoptosis, NR4A1 can thereby exert 
its mitogenic effects. For example in melanoma and lung cancer, NR4A1 mediates cell 
cycle progression and proliferation as well as angiogenesis, which was dependent on its 
transactivation and DNA binding ability [167, 239]. Furthermore, knockdown studies of 
NR4A1 in many cancer cell lines resulted in decreased cell growth and angiogenesis and 
increased apoptosis, providing further evidence for the role of NR4A1 as an oncogenic 
factor [67]. On the other hand, NR4A1 is downregulated in acute myeloid leukemia 
(AML), and Nr4a1/Nr4a3 knockout mice quickly develop AML, leading to the suspicion 
that NR4A1 is playing a tumor suppressive role in this blood cancer [156]. This seems to 
contradict its role in solid tumors, but it is more understandable after realizing that 
NR4A1 possesses the ability to exert opposing roles in different tissues and cell types. 
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NR4A1 can also wield its effects by other means, such as interacting with proteins from a 
multitude of signaling pathways, as well as phosphorylation by kinases to either promote 
or inhibit its translocation to the cytoplasm. As discussed below, miRNAs also factor into 
this regulation of NR4A1 activity by both direct and indirect effects, thereby affecting 
cancer progression in a myriad of ways. 
 
 
miRNAs That Directly Target NR4A1 
 
Currently there is a shortage of miRNAs that have been proven to target NR4A1. 
According to miRTarBase there are no miRNAs that have been validated to target NR4A1 
using strong evidence consisting of reporter assays, western blots, and qPCR. There are a 
total of 6 miRNAs shown to target NR4A1 using less strong evidence such as microarrays 
and next-generation sequencing (NGS). For example, one study used a microarray and 
found that HeLa cells transfected with miR-124 had decreased NR4A1 mRNA [240]. 
Another study also used a microarray and showed that rno-miR-290 targets Nr4a1 in the 
rat brain [241]. However, there is one recent study that does validate the targeting of 
NR4A1 by miR-124, miR-15a, and miR-224 through the use of reporter assays, western 
blot, and qPCR. This study also found that miR-124 can suppress the transcriptional 
activity of NR4A1 in Daoy medulloblastoma cells. When miR-124 was exogenously 
expressed in these cells, proliferation and viability were significantly decreased [242]. 
Although miR-124 is predicted to target many other genes, it is possible that it is causing 
these anti-tumor effects through the suppression of NR4A1. miR-124 is an interesting 
miRNA because it is the most abundant miRNA in the brain with a role in neuronal 
differentiation. It is a tumor suppressor in many cancer types, several of which express 
aberrantly low levels of this miRNA. Since NR4A1 is commonly upregulated in cancer, 
it is easy to see how this aberrant upregulation could be due to the downregulation of 
miRNAs that target it such as miR-124.  
 
 
miRNAs That Indirectly Affect NR4A1 Expression and Function 
 
 
Proteins that modulate NR4A1 mRNA expression 
 
There are several ways in which miRNAs may indirectly affect NR4A1 
expression and function. One way is by targeting proteins that modulate NR4A1 mRNA 
expression. For example, the histone acetyltransferase p300 can acetylate NR4A1, thereby 
enhancing its expression in HepG2 and HeLa cells [243]. In addition, the transcription 
factor AP-1 was shown to bind the promoter of NR4A1 and induce its expression in colon 
cancer cells after exogenous β-catenin expression [230]. β-catenin was also found to 
increase NR4A1 transcription through hypoxia-inducible factor 1-alpha (HIF-1α) in colon 
cancer cells in response to hypoxic conditions [244]. β-catenin is aberrantly activated in 
90% of colon tumors and acts as an oncogene in this cancer [230], therefore it would 
appear that β-catenin is exerting its proliferative effects partly through its induction of 
NR4A1. HIF-1α was also found to bind to the promoter of NR4A1 and promote its 
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expression in several cancer cell types including renal cell carcinoma, neuroblastoma 
[245], hepatocellular carcinoma (HCC), cervical cancer, and breast cancer [246]. EP300 
(encodes p300), FOS and JUN (comprises AP-1), CTNNB1 (encodes β-catenin), and 
HIF1A are targeted and repressed by many miRNAs as listed in Table 2-1. Upon 
repression of these genes by miRNAs, NR4A1 expression would also theoretically 
decrease. On the other hand, HDAC1 is able to repress NR4A1 in HepG2 and HeLa cells 
[243]. Therefore any miRNAs that target and suppress HDAC1 would result in enhanced 
NR4A1 expression.  
 
 
Proteins that directly bind NR4A1 
  
RXR. Another way miRNAs may indirectly affect NR4A1 is by targeting binding 
partners of NR4A1 that in turn affect its localization and function, as depicted in  
Figure 2-1. One of the most complex interactions may be with the retinoid X receptor 
(RXR). Depending on experimental conditions and external stimuli, RXR may 
heterodimerize with NR4A1 and either bind to DNA to modulate gene expression or 
localize to the mitochondria to induce apoptosis. When prostate and lung cancer cells 
were treated with apoptosis-inducing agents 3-Cl-AHPC and TPA (12-O-tetradecanoyl-
13-phorbol acetate), RXRα formed a heterodimer with NR4A1 and translocated to the 
mitochondria to induce apoptosis [162]. However, translocation of this heterodimer and 
subsequent apoptosis were inhibited by the RXR ligand 9-cis-retinoic acid (9-cis-RA) 
[162]. This RXR ligand along with RXR-selective retinoids, SR11246 and SR11345, 
strongly promote RXR/NR4A1 heterodimer binding to the retinoic acid response element 
βRARE [91, 162, 247, 248], although NR4A1 can also increase RA response element 
transcription independent of retinoic acid [247]. Contrary to this finding, one group found 
that 9-cis-RA actually enhanced RXR/NR4A1 dimerization and translocation to the 
mitochondria, along with subsequent apoptosis [249]. This group also found that NR4A1 
binding to RXR could suppress p300-mediated RXR acetylation, thereby decreasing the 
transcriptional and mitogenic activity of RXR [249]. It appears that the interactions and 
effects of NR4A1/RXR heterodimerization are dependent on many factors, and that 
seemingly contradictory findings may be due to differences in cell types among other 
factors. There are only a few miRNAs that directly target RXRA, including miR-128 and 
miR-574 [250, 251]. Therefore it is possible that expression of these miRNAs result in 
the opposite effects described here.   
 
COUP-TF. In addition to RXR, the COUP-TF (chicken ovalbumin upstream 
promoter-transcription factor) orphan receptors can also bind with NR4A1 and have 
varying effects. In the absence of ligand, COUP-TFs bind RAREs and inhibit their 
transcription, leading to decreased RARB and increased cell growth, at least in breast and 
lung cancer. However in the presence of RA, COUP-TF has no effect on βRARE 
transcription and therefore enhances the anti-tumor effects of RA, leading to the 
conclusion that COUP-TF sensitizes cancer cells to RA. In lung cancer cells, NR4A1 
heterodimerizes with COUP-TF and prevents binding to the βRARE, thereby 
desensitizing the cells to RA. On the other hand, COUP-TF can prevent NR4A1/RXR 
heterodimer binding to the βRARE via protein-protein interaction. Furthermore, COUP-
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Table 2-1. Effects of Nur77 regulatory networks on cancer and potential implications by miRNAs. 
 
Functional 
relationship to 
NR4A 
Gene 
(common 
name) 
Effect on NR4A/functional 
consequence 
Oncogenic 
effect? 
Cancer type/disease miRNAs 
miRNA 
references 
Modulates 
Nur77 mRNA 
expression 
EP300 
(p300) 
Promotes expression via acetylation  Yes Liver, cervical 20a, 26a, 106b~25, 132, 150, 
574 
[252-257] 
 Fos/Jun 
(AP-1) 
Promotes expression by directly 
binding to promoter 
Yes Colon 101, 181b, 155 [258-263] 
  HIF1A 
(HIF-1α) 
Promotes expression by directly 
binding to promoter 
Yes Neuroblastoma, 
cervical, breast, liver 
17~92, 18a, 20b, 31, 93, 138, 
155, 199ab, 206, 210, 335, 
338, 519c  
[264-279] 
 CTNNB1 
(β-catenin) 
Promotes expression via activation of 
AP-1 
Yes Colon 34, 185, 200abc, 203, 214, 
434, 680, 690 
[280-286] 
  HDAC1 Suppresses expression No Liver, cervical 34a, 449ab, 874               [287-294] 
Binds Nur77 
protein 
RXRA 
(RXRα) 
RXR/Nur77 heterodimer either 
activates transcription or translocates 
to mitochondria to induce apoptosis 
Yes and 
No 
Lung, pancreatic 128, 574 [250, 251] 
  NR2F2 
(COUP-TF) 
Binds and prevents Nur77 from 
binding to RXR, thereby resensitizing 
cells to RA 
Yes and 
No 
Lung 194, 302a [295, 296] 
 CHD1L Inhibits mitochondrial targeting Yes Liver None  
  XRCC5 
(Ku80) 
Nur77 prevents Ku80-mediated DNA 
repair 
No Liver 31, 526b [297, 298] 
 TP53 (p53) Nur77 blocks p53 transcriptional 
activity/promotes p53-mediated 
apoptosis 
Yes and 
No 
Lung, liver, bone 25, 30d, 125, 150, 375, 504, 
1285           
[299-305] 
  STK11 
(LKB1) 
Nur77 prevents LKB1 from 
suppressing mTOR 
Yes Cervical 155 [306] 
 PIN1 (Pin1) Pin1 promotes Nur77 transcriptional 
activity 
Yes Cervical 140, 200bc, 296 [307-309]   
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Table 2-1.  Continued. 
 
Functional 
relationship to 
NR4A 
Gene 
(common 
name) 
Effect on NR4A/functional 
consequence 
Oncogenic 
effect? 
Cancer type/disease miRNAs 
miRNA 
references 
  EP300 
(p300) 
Nur77 either inhibits p300 or forms 
complex to promote transcription 
Yes and 
No 
Cervical, breast, lung 20a, 26a, 106b~25, 132, 150, 
574 
[252-257] 
 CTNNB1 
(β-catenin) 
Nur77 inhibits β-catenin function No Colon 34, 185, 200abc, 203, 214, 
434, 680, 690 
[280-286] 
 NDRG1 Competitively binds Nur77 and 
prevents it from inducing β-catenin 
degradation 
Yes Liver 182, 769 [310, 311] 
  VHL 
(pVHL) 
Nur77 inhibits the pVHL-mediated 
ubiquitination of HIF-1α 
Yes Neuroblastoma, renal 
cell carcinoma 
21 [312] 
 NR0B2 
(SHP) 
SHP blocks Nur77 from 
transcriptionally mediating cell death 
upon treatment with an apoptosis-
inducer 
Yes Liver 141, 378g, 4649 [313-315] 
  PRKCA 
(PKC) 
Nur77 prevents PKC from activating 
AP-1 and NF-kB 
No Acute T cell leukemia 24-2 [316] 
 PML Inhibits Nur77 transcriptional activity No osteosarcoma None  
Phosphorylates 
Nur77 
AKT1 (Akt) Nur77 mitochondrial targeting is 
blocked by Akt 
Yes Gastric 100, 105, 133b, 143, 149, 342 [317-322] 
 JNK JNK induces Nur77 mitochondrial 
targeting and inhibits its transcriptional 
activity 
No Lung, prostate, breast, 
glioma, ovarian, oral 
squamous cell 
carcinoma 
92a [323] 
  PRKDC 
(DNA-
PKcs) 
Nur77 induces apoptosis upon ionizing 
radiation treatment, which is dependent 
on its phosphorylation by DNA-PKcs 
No Liver 101 [324] 
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Table 2-1. Continued. 
 
Functional 
relationship to 
NR4A 
Gene 
(common 
name) 
Effect on NR4A/functional 
consequence 
Oncogenic 
effect? 
Cancer type/disease miRNAs 
miRNA 
references 
 GSK3B 
(GSK-3β) 
Nur77 is blocked from inhibiting B-
catenin transcriptional activity upon 
phosphorylation by GSK-3B 
Yes Colon 26a, 346 [325, 326] 
Transcriptional 
target of Nur77 
CCND2 
(cyclin D2) 
Promotes proliferation via cyclin D2 Yes Cervical 1, let-7a, 15b, 16, 26a, 29abc, 
30c, 98, 124a,  145, 182, 195, 
198, 204, 206, 302b, 340, 375, 
497, 610 
[327-350] 
 TXNDC5 Promotes lower stress levels and 
therefore increased survival 
Yes Pancreatic 200b [351] 
  BIRC5 
(survivin) 
Promotes survival Yes Pancreatic 16, 195~497, 203, 218, 542, 
708 
[352-361] 
  E2F1 TPA induces Nur77, resulting in 
increased E2F1 and apoptosis; Pin1 
promotes Nur77 to transcriptionally 
activate E2F1, resulting in increased 
proliferation 
Yes and 
No 
Prostate, cervical 106a, 136, 149, 205, 223, 320, 
326, 329, 330, 331, 342, 362, 
493, 603 
[321, 362-
374] 
 
  CDK4 Nur77 activates CDK4 following 
induction by bile acids 
Yes Liver, colon 1, 34a, 124, 188, 195, 206, 
486, 506, 613 
[341, 375-
387] 
  BRE Nur77 activates BRE following 
induction by bile acids 
Yes Liver, colon None   
  RBBP8 Nur77 activates RBBP8 following 
induction by bile acids 
Yes Liver, colon 19ab, 335 [388, 389] 
  MAP4K5 Nur77 activates MAP4K5 following 
induction by bile acids 
Yes Liver, colon None   
  STAT5A Nur77 activates STAT5A following 
induction by bile acids 
Yes Liver, colon 141, 222, 223, 1469 [390-393] 
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Table 2-1.  Continued. 
 
Functional 
relationship to 
NR4A 
Gene 
(common 
name) 
Effect on NR4A/functional 
consequence 
Oncogenic 
effect? 
Cancer type/disease miRNAs 
miRNA 
references 
  BID Nur77 activates BID following 
induction by bile acids 
No Liver, colon None   
  POMC Nur77 promotes POMC expression Yes Cushing's disease None   
  CITED1 Nur77 represses CITED1, allowing 
Wnt activation 
Yes Melanoma None   
  DACT1 Nur77 represses DACT1, allowing 
Wnt activation 
Yes Melanoma None   
  MYC Nur77 represses MYC No Acute myeloid 
leukemia 
let-7g, 24, 34abc, 126, 135b, 
145, 185, 320b, 487b, 494, 
744 
[394-408] 
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Figure 2-1. NR4A1 mediates cell proliferation and survival in addition to cell 
death. 
The top panel depicts genes that transcriptionally activate NR4A1, leading to NR4A1 
interactions that ultimately promote cell proliferation and survival. In contrast, the bottom 
panel details the actions of NR4A1 in response to apoptotic stimuli, resulting in 
translocation of NR4A1 to the mitochondria and induction of apoptosis. 
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TF expression was positively correlated with RA sensitivity, while NR4A1 expression 
was associated with retinoid resistance in lung cancer cells. This suggests NR4A1 is 
responsible for RA resistance, leading to enhanced cell proliferation [247]. miRNAs 
capable of directly binding and suppressing NR2F2 (encodes COUP-TF) include miR-
194 and miR-302a. COUP-TF suppresses osteoblastic differentiation, and overexpression 
of miR-194 and miR-302a was found to rescue this effect [295, 296]. This leads us to 
speculate that expression of these miRNAs would result in the desensitization of cancer 
cells to RA treatment mediated by NR4A1.  
 
CHD1L. The next gene that physically interacts with NR4A1 is CHD1L. This 
protein acts as an oncogene in hepatocellular carcinoma and can bind with NR4A1 to 
prevent its translocation to the mitochondria and subsequent apoptosis upon treatment 
with staurosporine [409]. Unfortunately, there are no miRNAs that have been validated to 
target CHD1L. However, CHD1L interacts with Ku70 and DNA-dependent protein 
kinase, catalytic subunit (DNA-PKcs) to enhance chromatin remodeling and DNA repair 
[410, 411], although its elevated levels in cancer surprisingly lead to increased DNA 
damage. The DNA-PK complex is essential for mediating double-strand break repair and 
comprises DNA-PKcs and Ku70/Ku80. Since NR4A1 is known to interact with Ku80 to 
suppress DNA repair [232] and has also been shown to bind CHD1L, it is possible that 
NR4A1 inhibits DNA repair via protein-protein interactions with Ku80 and/or CHD1L. 
There are presently two miRNAs shown to target XRCC5 (encodes Ku80), including 
miR-31 and miR-526b [297, 298]. Therefore expression of these miRNAs may lead to 
increased DNA damage, which would most likely lead to cell death.    
 
p53. One of the more significant binding partners of NR4A1 is the tumor 
suppressor p53, and similar to some of its previously discussed binding partners, this 
interaction can lead to contradictory outcomes. NR4A1 can play an oncogenic role by 
binding to p53 and preventing p300 acetylation of p53, resulting in suppressed p53 
transcriptional activity [412]. In addition, NR4A1 can circuitously promote oncogenic 
mTOR signaling by inhibiting p53-mediated transcription of sestrin-2, an activator of 
AMPK, which is an inhibitor of mTOR [238, 413]. However in the presence of DNA-
PKcs, NR4A1 is phosphorylated by DNA-PKcs and becomes an activator of p53 
transcriptional activity via phosphorylation of p53 by DNA-PKcs. In addition to 
increasing p53 transactivation, NR4A1 heterodimerization with p53 can enhance p53-
mediated apoptosis as well as p53 protein stability by blocking ubiquitination and 
subsequent degradation of p53 by MDM2 [412]. As listed in Table 2-1, many miRNAs 
have been found to target TP53. Since p53 is a tumor suppressor, this would imply that 
any miRNA that targets it is likely an oncomiR.  
 
LKB1. Another way in which NR4A1 promotes mTOR signaling is by inhibiting 
LKB1. NR4A1 binds LKB1 and blocks it from activating AMPK, thereby preventing 
AMPK from inhibiting mTOR. This leads to enhanced mTOR signaling and therefore 
increased proliferation, survival, and angiogenesis [414]. Interestingly, miR-155 was 
found to promote proliferation of cervical cancer cells by targeting STK11 (encodes 
LKB1), therefore acting as an oncomiR [306]. 
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Pin1 and p300. Additional proteins that interact with NR4A1 include p300 and 
Pin1. NR4A1 isomerization and increased protein stability is mediated by Pin1 and 
enhances recruitment of p300, thereby increasing the transcriptional activity of NR4A1 
and its downstream proliferative effects [415]. NR4A1 can also form a complex with 
p300 and Sp1 to promote expression of proliferative and prosurvival genes such as 
survivin in lung cancer cells [238]. On the other hand, NR4A1 can directly interact with 
p300 and block its ability to acetylate transcription factors, thereby repressing their 
transcriptional activity and resulting in decreased proliferation in breast cancer cells 
[416]. Five miRNAs target EP300, including miR-20a [252], miR-132 [256], miR-150 
[254], and miR-574 [253], as well as the miR-106b~25 cluster [255]. In addition, miR-
200b [307], miR-200c [308], and miR-296 [309] were found to target PIN1. All of these 
miRNAs, with the exception of miR-20a and the miR-106b~25 cluster, play mostly 
tumor suppressive roles. Therefore it would make sense that expression of these miRNAs 
would have a negative impact on NR4A1 function via targeting of EP300 and PIN1.  
 
β-catenin. The proto-oncogene β-catenin is often mutated in cancer and interacts 
with transcription factors to promote expression of mitogenic genes. NR4A1 acts as a 
negative regulator of β-catenin function either by inducing its degradation in the 
cytoplasm [417] or by blocking its interaction with the transcription factor TCF4 and 
promoting recruitment of corepressors, thereby suppressing its transcriptional activity in 
colon cancer [418]. In contrast, NR4A1 was found to activate and stabilize β-catenin 
protein and prevent its degradation under hypoxic conditions via NR4A1-mediated 
activation of the Akt pathway. As mentioned, β-catenin can promote NR4A1 expression, 
thereby forming a positive feedback loop that promotes the proliferation of colon cancer 
cells [244]. CTNNB1 (encodes β-catenin) is targeted by miR-34 [280, 419], miR-200a 
[282-284], and miR-214 [285, 286], all of which act as tumor suppressors in several 
cancer types. Five other miRNAs have also been shown to directly target CTNNB1 [281], 
and expression of these miRNAs may either relieve NR4A1 of its inhibitory effect on β-
catenin, or suppress the NR4A1-mediated activation of β-catenin induced by hypoxia. 
 
NDRG1. N-myc downstream regulated gene 1 (NDRG1) acts as an oncogene in 
hepatocellular carcinoma by promoting β-catenin accumulation. It does so by 
competitively binding with glycogen synthase kinase-3β (GSK-3β) and NR4A1 
individually, thus preventing β-catenin degradation by GSK-3β and NR4A1. This 
inhibitory mechanism by NDRG1 results in upregulation of downstream oncogenic genes 
[420]. miR-182 acts as an oncomiR in prostate cancer [310] while miR-769 [311] plays a 
tumor suppressive role in breast cancer, both of which mediate their effects by directly 
targeting NDRG1. However in HCC, expression of these miRNAs would presumably 
result in increased β-catenin degradation via NR4A1 and GSK-3β, thus leading to anti-
proliferative effects.   
 
SHP. Small heterodimer partner (SHP) commonly inhibits nuclear receptor 
function via physical interaction and was found to bind and suppress NR4A1 
transcriptional activity. When HCC cells were treated with an inducer of apoptosis, SHP 
prevented NR4A1 from transcriptionally mediating cell death [421]. There are three 
miRNAs that target NR0B2 (encodes SHP), including miR-141 [313], miR-378g [314], 
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and miR-4649 [315], expression of which would theoretically lead to enhanced apoptosis 
mediated by NR4A1. 
 
PKC. As mentioned briefly, NR4A1 appears to be a tumor suppressor in 
leukemia. One way NR4A1 may mediate this effect is by interacting with and inhibiting 
protein kinase C (PKC). In Jurkat leukemic T cells, the LBD of NR4A1 binds PKC and 
prevents it from activating AP-1 and NF-kB [422]. The activation of NF-kB by PKC can 
lead to induction of anti-apoptotic genes, and since NR4A1 is known to induce apoptosis 
in T cells, its inhibition on PKC may be necessary in order for apoptosis to occur. miR-
24-2 is the only miRNA that has been shown to directly target PRKCA (PKC) and was 
found to decrease cell survival in breast cancer cells via PKC inhibition [316]. 
 
PML. Another way NR4A1 is involved in leukemia is through its interaction with 
the promyelocytic leukemia gene, PML [423]. Patients with acute promyelocytic 
leukemia commonly have a chromosomal translocation that results in fusion genes 
encoding PML-RARα and RARα-PML [424]. PML is well known for its ability to inhibit 
cell proliferation and to act as a tumor suppressor in vivo [425-429]. PML was also found 
to directly interact with NR4A1 in its DBD domain and prevent its transcriptional activity 
in osteosarcoma cells [423]. Thus far there have not been any miRNAs found to target 
PML, but hypothetically any miRNA that suppresses PML would result in increased 
transcriptional activity by NR4A1.  
 
VHL. Lastly, the tumor suppressor von Hippel-Lindau (pVHL) is an E3 ubiquitin 
ligase that forms a multimeric complex to degrade proteins and has been implicated in 
several diseases as a result of mutations in pVHL. One of its target proteins is HIF-1α, 
which gets ubiquitinated upon binding with pVHL and subsequently degraded. However, 
NR4A1 is able to bind pVHL and prevent this HIF-1α ubiquination [430]. As mentioned, 
HIF-1α can transcriptionally promote expression of NR4A1, which was shown in VHL-
deficient renal cell carcinoma [245], as well as other cancer cell lines [246]. Since both 
NR4A1 and HIF-1α are known to enhance expression of oncogenic genes via their 
transactivation functions, it is understandable that they would have a synergistic effect. 
VHL is targeted by miR-21 [312], expression of which would result in increased HIF-1α 
protein stability and transcriptional activity.  
 
 
Proteins that phosphorylate NR4A1 
 
Akt. Furthermore, miRNAs may target protein kinases that are responsible for the 
copious amounts of phosphorylation endured by NR4A1 on its N-terminus [86]. Some of 
these kinases positively regulate NR4A1 and mediate either its cell death or cell 
proliferation effects, while other kinases block these functions. Most studies that involve 
NR4A1-mediated apoptosis use external stimuli to force these effects. For example, 
gastric cancer cells treated with TPA experience cell death due to the translocation of 
NR4A1 to the mitochondria and ensuing induction of apoptosis. However, 
phosphorylation of NR4A1 by Akt, a serine/threonine kinase, blocks the mitochondrial 
targeting of NR4A1 along with its interaction with Bcl-2 [431]. Other studies have also 
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verified this negative effect of Akt on NR4A1-induced apoptosis, as well as an inhibitory 
effect on NR4A1 transcriptional activity [121, 432]. Furthermore, CHD1L indirectly 
activates Akt, leading to inhibition of cell death [433]. As discussed, CHD1L is also able 
to block apoptosis by directly binding NR4A1; therefore the activation of Akt is an 
additional mechanism by which CHD1L can prevent cell death via inhibition of NR4A1. 
miRNAs that target AKT1 would theoretically alleviate the suppression of NR4A1 by 
Akt. Several of these miRNAs act as tumor suppressors, including miR-105 and miR-
133b, which were found to act as tumor suppressors in HCC and bladder cancer, 
respectively, via inhibition of AKT1 [318, 319]. 
 
JNK. On the other hand, phosphorylation of NR4A1 by c-Jun N terminal kinase 
(JNK) promotes the translocation and mitochondrial targeting of NR4A1. This NR4A1-
mediated apoptosis occurs in the presence of several different cytotoxic compounds. 
Many of these compounds also upregulate NR4A1 expression, including 6-[3-(1-
adamantyl)-4-hydroxyphenyl]- 2-naphthalene carboxylic acid (AHPN). This retinoid is a 
potent inducer of apoptosis in several cancer types, and addition of 3-Cl-AHPC (an 
analog of AHPN) to lung, prostate, and breast cancer cells induces phosphorylation of 
NR4A1 by JNK followed by its translocation to the mitochondria and subsequent 
apoptosis [167, 434]. Treatment of lung cancer cells with 3-Cl-AHPC also inhibits 
NR4A1 transcriptional activity [167]. In addition, apaensin, a plant-derived natural 
product, induces apoptosis in lung and breast cancer cells via NR4A1, which is mediated 
by JNK phosphorylation [435]. Furthermore, glioma and oral squamous cell carcinoma 
treated with PCH4, a derivative of n-butylidenephthalide, induced apoptosis, which was 
dependent upon the mitochondrial targeting of NR4A1 mediated by JNK [436, 437]. 
Interestingly, the nuclear export of NR4A1 occurs in cisplatin-sensitive ovarian cancer 
cells but not in cisplatin-resistant cells. Cisplatin-induced apoptosis is dependent on the 
translocation of NR4A1 mediated by JNK phosphorylation [179]. There are no known 
miRNAs that target human MAPK8 (JNK), although miR-92a has been shown to target 
mouse Mapk8 [323]. Expression of miR-92a would hypothetically suppress NR4A1 
translocation and instead allow for cell survival and proliferation via inhibition of JNK.    
 
DNA-PKcs. In addition to JNK, DNA-PKcs also positively regulates NR4A1. 
DNA-PKcs phosphorylates NR4A1 and increases its protein levels in liver cancer cells. 
As mentioned previously, this phosphorylation of NR4A1 enhances the transcriptional 
activity and phosphorylation of p53 by DNA-PK. Hepatoma cells treated with ionizing 
radiation (IR) leads to DNA-PKcs-mediated upregulation of NR4A1, which results in 
apoptosis induced by NR4A1 [232]. miR-101 was found to sensitize glioma and lung 
tumors to radiation via direct suppression of PRKDC (encodes DNA-PKcs) [324]. 
Paradoxically, decreased PRKDC by miR-101 should result in reduced NR4A1-mediated 
apoptosis, but perhaps miR-101-mediated apoptosis is occurring via NR4A1-independent 
mechanisms.     
 
GSK-3β. As stated earlier, NR4A1 prohibits the transcriptional activity of β-
catenin by disrupting the DNA binding of β-catenin and TCF4 and promotes the 
recruitment of corepressors to Wnt target genes, thereby attenuating tumor growth. 
However, this negative regulation by NR4A1 is prevented upon phosphorylation by 
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GSK-3β, which is a phenomenon observed in most clinical colorectal cancers [418]. This 
phosphorylation of NR4A1 by GSK-3β allows β-catenin to transcriptionally activate 
genes involved in cell proliferation, leading to cancer progression. This may seem 
contradictory to the main function of GSK-3β, which is to promote degradation of β-
catenin, leading to tumor suppression. However in colorectal cancer, GSK-3β may have 
evolved in the tumor microenvironment to instead support β-catenin activity via 
inhibition of NR4A1. Therefore in this scenario, miRNAs that target and inhibit GSK3B 
should lead to decreased tumor growth since GSK-3β can no longer prevent NR4A1-
mediated degradation of β-catenin. miR-26a promotes cholangiocarcinoma [325] and 
miR-346 promotes osteogenic differentiation [326], both of which mediate their effects 
by directly targeting GSK3B.  
 
 
Target genes of NR4A1 
 
Proliferation and survival genes. Lastly, miRNAs may attenuate the 
transcriptional activity of NR4A1 by targeting and suppressing the expression of NR4A1 
target genes. Transcriptional targets of NR4A1 that mediate its proliferation and survival 
functions include CCND2 (cyclin D2) [415], E2F1 [415, 438], thioredoxin domain 
containing 5 (TXNDC5) [439], and BIRC5 (survivin) [233, 238]. Many of these genes act 
as oncogenes, for example survivin is overexpressed in many cancers including 
pancreatic cancer, where it was found that NR4A1-induced survivin expression is 
essential for pancreatic cancer cell growth [233, 238]. In addition to survivin, TXNDC5 
is also upregulated in several cancer types and was found to promote proliferation and 
migration while decreasing apoptosis in gastric cancer cells [440]. TXNDC5 is induced 
by NR4A1 in pancreatic cancer cells, leading to lower stress levels that permit increased 
cancer cell growth and survival [439]. Cyclin D2 and E2F1 expression induced by 
NR4A1 was also found to increase cell proliferation [415], although induction of NR4A1 
by TPA actually resulted in increased apoptosis via E2F1 in prostate cancer cells [438]. 
Numerous miRNAs have been found to directly target these genes, and expression of 
these miRNAs typically results in decreased proliferation and survival (Table 2-1).  
 
Pro-inflammatory genes. Furthermore, liver and colon cancer cells treated with 
bile acids (BAs) experienced a substantial increase in NR4A1 expression, leading to the 
upregulation of pro-inflammatory genes subsequently identified as NR4A1 target genes. 
These include CDK4, CCND2, BRE, RBBP8, MAP4K5, and STAT5A, which most likely 
mediate the increased proliferation and migration observed upon BA-induced NR4A1 
overexpression [231]. Surprisingly, NR4A1 was also found to induce the proapoptotic 
gene BID [231]. miRNAs that target and suppress the expression of NR4A1 target genes 
would therefore attenuate the effects of NR4A1 transcriptional activity, and in this case 
the miRNAs would act as tumor suppressors in liver and colon cancers (Table 2-1).     
 
POMC. An RXR agonist, HX630, suppresses NR4A1 and its transcriptional 
induction of pro-opiomelanocortin (POMC), leading to the inhibition of corticotroph 
tumor growth [441]. Corticotroph tumors that secrete excessive amounts of 
adrenocorticotropic hormone (ACTH) can develop into Cushing’s disease [441]. 
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Therefore, NR4A1-mediated induction of POMC may lead to the formation of 
corticotroph tumors and downstream Cushing’s disease. miRNAs that block expression 
of POMC would thus decrease the formation of corticotroph tumors and the likelihood of 
Cushing’s disease. Unfortunately, no miRNAs have been verified to target POMC as of 
yet.  
 
Negative regulators of Wnt. Over 70% of melanomas have a mutation in NRAS 
or BRAF, resulting in aberrant and constitutive signaling of the MAPK pathway and 
downstream proliferative effects. When NR4A1 is knocked down in melanoma cells via 
siRNA, antagonists of the Wnt pathway, DACT1 and CITED1, were upregulated [442]. 
Therefore, NR4A1 acts to transcriptionally suppress these antagonists, resulting in the 
continued activation of the Wnt pathway. This further supports the role of NR4A1 as an 
oncogenic factor, especially in the case of melanoma since NR4A1 has the highest 
expression in this cancer compared to all other cancer types. Currently, there are no 
known miRNAs that target DACT1 and CITED1, although several miRNAs are predicted 
to target DACT1 in the TargetScan database. Expression of these predicted miRNAs 
would theoretically support the function of NR4A1 and promote activation of the Wnt 
pathway.    
 
Myc and Bcl-2. On the other hand, NR4A1 plays a tumor suppressive role in 
AML by binding to the promoter of MYC and suppressing its transcription, thereby 
preventing its downstream oncogenic effects. NR4A1 was also found to decrease BCL2 
expression, although it is unclear if it directly binds the promoter. Myc and Bcl-2 work 
together to promote AML, therefore NR4A1-mediated suppression of BCL2 further 
attenuates the oncogenic activity of Myc. Furthermore, the leukemogenicity of AML 
cells was prevented by overexpression of NR4A1 in vivo [443]. There are many miRNAs 
that target MYC and BCL2, and expression of these miRNAs would support the role of 
NR4A1 as a tumor suppressor in AML.    
 
 
Conclusions 
 
The regulatory proteins listed in this chapter are not an exhaustive list of those 
that regulate and interact with NR4A1. There are many others that target it in different 
contexts, however only the proteins that have been shown to target and regulate NR4A1 
in the context of cancer are discussed. A more thorough review that was recently 
published includes all interacting factors of NR4A1 and its family members and explores 
how these interactions affect various physiological processes [444]. 
 
In addition to the proteins discussed here, other transcription factors such as Sp1, 
NF-kB, and CREB have all been shown to bind the promoter of NR4A1 to modulate its 
expression [137, 445, 446]. Other binding partners also include NFAT, GATA4, SRC-2, 
and c-JUN [77, 447-449]. An important binding partner of NR4A1 that mediates the 
apoptotic effect of NR4A1 is Bcl-2 [123]. Additional kinases such as ERK2, ERK5, 
RSK2, and p38α also phosphorylate NR4A1 [450-453]. Furthermore, NR4A1 has been 
shown to bind the promoters and modulate expression of EDN1 (endothelin 1) and 
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ITGB4 (integrin beta 4) [448, 454]. However, these proteins were not discussed in detail 
since the experiments were performed in relatively normal cell lines. Due to the fact that 
NR4A1 may play different and opposing roles depending on the cell line, it is possible 
that it may also have different functions in cancer cells compared to normal cells. 
Because NR4A1 appears to play an oncogenic role in cancer, this chapter discusses the 
proteins that regulate NR4A1 in a malignant environment.      
 
Many of the miRNAs discussed here correlate well with the role of NR4A1 in 
cancer. Those miRNAs that are typically overexpressed in cancer and act as oncomiRs 
appear to support the oncogenic functions of NR4A1 by suppressing proteins that would 
otherwise attenuate the actions of NR4A1 or repress oncogenic pathways. On the other 
hand, many of the miRNAs that target genes involved in NR4A1-mediated cancer 
progression are known tumor suppressors. All of the miRNAs discussed and listed in 
Table 2-1 have been verified to target their aforementioned targets using luciferase 
assays in which the seed region was mutated to confirm direct binding, and most of them 
were further verified by qPCR and western blot analysis.   
 
It is important to note that in instances where NR4A1 mediates apoptosis in 
cancer cells, it is being induced to do so upon treatment with cytotoxic compounds. 
Therefore in the absence of external stimuli, it seems that the normal role of NR4A1 in 
cancer is to transcriptionally promote expression of genes that are important in cell 
proliferation and survival. 
 
According to the latest research, there are numerous studies portraying NR4A1 as 
an oncogenic factor. Glancing at Table 2-1, it is apparent that NR4A1 exerts is mitogenic 
effects via several mechanisms. These include transcriptional regulation by other 
transcription factors, protein-protein interactions, post-translational modifications such as 
phosphorylation, and directly binding the promoters of target genes to drive their 
expression towards a proliferative and pro-survival state. Understanding these regulatory 
networks is imperative in order to develop more efficacious and personalized treatment 
for cancer patients. 
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CHAPTER 3.    REGULATION OF NUCLEAR RECEPTOR NR4A1 BY 
MIR-124* 
 
 
Introduction 
One of the ten hallmarks of cancer is uncontrolled and limitless cell growth. Cells 
that have acquired the capability to proliferate indefinitely form tumors that may 
metastasize and develop into cancer. In some cancers, this proliferative signaling is 
controlled by certain genes that are often overexpressed and thereby constitute ideal 
therapeutic targets. Some of these target genes include nuclear receptors such as the 
estrogen receptor in breast cancer or the androgen receptor in prostate cancer. Another 
nuclear receptor that researchers have identified as a potential therapeutic target is 
NR4A1. 
The nuclear receptor NR4A1 is commonly upregulated in adult cancers and has 
oncogenic functions. NR4A1 is an immediate-early response gene that acts as a 
transcription factor to promote proliferation and protect cells from apoptosis. Conversely, 
NR4A1 can translocate to the mitochondria and induce apoptosis upon treatment with 
various cytotoxic agents. The roles of NR4A1 in cancers have been investigated mostly 
in adult cancers, with very few studies in childhood malignancies. NR4A1 is 
downregulated in leukemia, and Nr4a1/Nr4a3 double-knockout mice quickly develop 
acute myeloid leukemia before succumbing to the disease [156]; however, the expression 
and function of NR4A1 have not been well studied in pediatric solid tumors. Recent data 
from the Pediatric Cancer Genome Project show that NR4A1 is deleted in many 
hypodiploid acute lymphoblastic leukemia tumors, whereas it is amplified in some 
patients with Group 4 medulloblastoma (MB) and rhabdomyosarcoma [455]. 
 
Because NR4A1 is upregulated in cancer and may have a role in cancer 
progression, it is of interest to understand the mechanism controlling its expression. 
MicroRNAs (miRNAs) are responsible for inhibiting translation of their target genes by 
binding to the 3ʹUTR and either degrading the mRNA or preventing it from being 
translated into protein, thereby making these non-coding endogenous RNAs vital 
regulators of every cellular process. Several miRNAs have been predicted to target 
NR4A1; however, strong evidence showing the regulation of NR4A1 by any miRNA is 
lacking. In this study, we used a luciferase reporter assay containing the 3ʹUTR of NR4A1 
to screen 296 miRNAs and found that miR-124, which is the most abundant miRNA in 
the brain and has a role in promoting neuronal differentiation, caused the greatest 
reduction in luciferase activity. Interestingly, we discovered an inverse relationship in 
Daoy medulloblastoma cells and undifferentiated granule neuron precursors in which 
NR4A1 is upregulated and miR-124 is downregulated. Exogenous expression to further  
 
--------------------- 
*Modified with permission from PLOS ONE. Tenga, A., et al., Regulation of Nuclear 
Receptor Nur77 by miR-124. PLOS ONE, 2016. 11(2): p. e0148433.  
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elevate NR4A1 levels in Daoy cells increased proliferation and viability, but knocking 
down NR4A1 via siRNA resulted in the opposite phenotype. Importantly, exogenous 
expression of miR-124 reduced NR4A1 expression, cell viability, proliferation, and 
tumor spheroid size in 3D culture. In all, we have discovered miR-124 to be 
downregulated in instances of medulloblastoma in which NR4A1 is upregulated, 
resulting in a proliferative state that abets cancer progression. This study provides 
evidence for increasing miR-124 expression as a potential therapy for cancers with 
elevated levels of NR4A1.   
 
 
Methods 
 
 
Cell culture  
 
Human embryonic kidney cell line 293T (ATCC CRL-3216), human cortical 
neuronal cell line HCN-2 (ATCC CRL-10742), human medulloblastoma cell lines D341 
(ATCC HTB-187) and Daoy (ATCC HTB-186), and human rhabdomyosarcoma cell 
lines RD (ATCC CCL-136) and SJCRh30 (ATCC CRL-2061) were obtained from ATCC 
(Manassas, VA). Cells were free from contamination of mycoplasma, and passaged for 
fewer than 6 months after receipt (or resuscitation). Human rhabdomyosarcoma cell line 
Rh41 has been described previously [456]. 293T, HCN-2, and RD cells were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM). Rh41 and Rh30 cells were grown in 
RPMI-1640 Medium, and Daoy cells were cultured in Eagle’s Minimum Essential 
Medium (EMEM). UKF-NB-3 (NB3) cells, which originated from a patient with MYCN-
amplified stage 4 neuroblastoma [457], were cultured in Iscove’s Modified Dulbecco’s 
medium (IMDM). LHCN-M2 cells (immortalized myoblasts derived from the pectoralis 
major muscle [458]) were plated in gelatin-coated plates (0.1% gelatin in PBS) and 
cultured in DMEM supplemented with 15% FBS, 0.02M HEPES, 0.03 µg/mL zinc 
sulfate, 1.4 µg/mL vitamin B12, 0.055 µg/mL dexamethasone, 2.5ng/mL hepatocyte 
growth factor (recombinant human), and 10 ng/mL basic fibroblast growth factor. All 
cells were cultured at 37°C in 5% CO2, and all media (except LHCN-M2 media) were 
supplemented with 10% fetal bovine serum, 1% GlutaMAX, 1% sodium pyruvate, and 
1% penicillin-streptomycin (Life Technologies, Carlsbad, CA). 
 
 
Reporter assay 
 
For the miRNA screen, all miRNA constructs were obtained from an existing 
library [459]. These constructs are plasmids containing the pre-miRNA sequences and 
have been reconstituted in TE (10 mM Tris-HCl, pH 8.0; 0.1 mM EDTA, pH 8.0) buffer. 
Each miRNA construct (0.09 μg) was first added to the well of a 96-well plate 
(PerkinElmer, Waltham, MA) that were kept at 4°C until all miRNAs were plated. Next, 
0.15 μg of NR4A1-3ʹUTR reporter plasmid (NR4A1-3ʹUTR-Luc; GeneCopoeia, 
Rockville, MD) and 3 μL/μg of FuGENE 6 (Promega, Madison, WI) were mixed with 50 
μL of Opti-MEM reduced-serum media (Life Technologies) and dispensed into each well 
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before being overlaid with 293T cells (20,000 cells/well in 50 μL of antibiotic-free 
media). NR4A1-3ʹUTR-Luc (in the pEZX-MT01 vector) contains both the firefly 
luciferase gene (FLuc) fused upstream of the 3ʹUTR of NR4A1 under the control of the 
SV40 promoter and the Renilla luciferase gene (RLuc) under the control of the CMV 
promoter. RLuc was used as an internal transfection control. After 48 hours, the Dual-Glo 
luciferase assay system (Promega) was used to detect luciferase activity according to the 
manufacturer’s instructions. Raw luciferase activity was measured by using the EnVision 
2101 Multilabel Plate Reader (PerkinElmer). Raw values were normalized by dividing 
the FLuc values by the RLuc values and then normalized to the value of either pSIF, an 
empty vector control for miRNA that contains a scrambled sequence in place of the pre-
miRNA sequence [459], or oligo control (Cntrl) in the miR-124 inhibitor assay. The 
FLuc/RLuc values for pSIF or Cntrl were set as 1. Mutations in the 3ʹUTR of NR4A1 that 
disrupt the binding site of the miRNAs were made by Mutagenex (Suwanee, GA).   
 
 
RNA isolation and quantitative real-time PCR 
 
Total RNA, including miRNA, was extracted by using the Qiagen miRNeasy kit 
(Qiagen, Venlo, Netherlands); the Maxwell 16 LEV simplyRNA Tissue Kit was used 
with the Maxwell 16 Research Instrument (Promega) for RNA extraction only when 
miRNA extraction was not needed. RNA was converted to cDNA by using the 
SuperScript VILO cDNA Synthesis Kit (Life Technologies), and 2 μL of 5X Taqman 
probes (Applied Biosystems) specific to each miRNA were added to enhance miRNA 
detection. Target gene mRNA expression was detected by using specific Taqman probes 
(20X) and quantitated via the 7900HT Fast Real-Time PCR System (Applied 
Biosystems). GAPDH (4352934E) was used as an endogenous control for all gene 
expression analysis, including NR4A1 (Assay ID Hs00374226_m1), E2F1 (Assay ID 
Hs00153451_m1), CCND2 (Assay ID Hs00153380_m1), BIRC5 (Assay ID 
Hs04194392_s1), TXNDC5 (Assay ID Hs01046709_mH), CDK4 (Assay ID 
Hs01565683_g1), and STAT5A (Assay ID Hs00234181_m1). Both RNU6B (Assay ID 
001093) and RNU48 (Assay ID 001006) were used as endogenous controls for miRNA 
expression. RNU48 was used instead of RNU6B to analyze endogenous miRNA 
expression in the cell lines because RNU48 had less variable Ct values among cell lines. 
The probes used to detect miRNA levels (Applied Biosystems) were miR-124-3p (Assay 
ID 001182), miR-15a-5p (Assay ID 000389), and miR-224-5p (Assay ID 002099). 
Gapdh (4352932E) and Nr4a1 (Assay ID Mm01300401_m1) mouse probes were used to 
detect Gapdh and Nr4a1 expression in mice. snoRNA202 (Assay ID 001232) was used as 
an endogenous control for miR-124 expression in mice as recommended by Applied 
Biosystems [447]. The fold-change in expression was calculated by using the 
comparative Ct (ΔΔCt) method, with the values of controls set to 1. All samples were 
tested in quadruplicate. The Cancer miRNAs Transcriptome PCR Array (SA-
Biosciences, MD) was used to identify potential miRNAs that target NR4A1. The array 
was provided by the manufacturer in a 96-well PCR plate, each well containing cDNA 
sample synthesized from HeLa cells treated with one of 90 cancer-related miRNA 
mimics. According to the manufacturer’s instruction, we added qPCR MasterMix and 
NR4A1 probe and performed qPCR. We used the data analysis software provided by 
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SABiosciences to analyze qPCR data and determine which miRNAs affect NR4A1 
expression.   
 
 
miR-124 inhibitor assay 
 
Daoy cells were plated at a density of 100,000 cells per well in 6-well BD Falcon 
plates (Corning, Corning, NY). After 24 hours, the cells were first transfected with 
various concentrations of the miR-124-3p inhibitor (single-stranded RNA molecule) or 
the control oligonucleotide (oligo) for 24 hours at 37°C and then transfected with 1 μg of 
the NR4A1-3ʹUTR-Luc reporter plasmid. Transfecting the miR-124-3p inhibitor first 
allowed it to sufficiently inhibit the miR-124 activity before transfection of the NR4A1-
3ʹUTR-Luc reporter plasmid. After 24 hours of incubation, the cells were reseeded at a 
density of 4,000 cells per well in a 96-well plate, with 6 wells used for each condition. 
The DualGlo reporter assay was performed 48 hours later. The mirVana inhibitor from 
Life Technologies and the Power inhibitor from Exiqon (Woburn, MA) were both used to 
obtain the inhibitor data as indicated in the figure legends; each was used with a control 
oligo from their respective manufacturers. The Lipofectamine RNAiMAX transfection 
reagent (Life Technologies) was used with both inhibitors.  
 
 
Transfections 
 
Cells were transfected with miRNAs by using Fugene6 (Promega) in Opti-MEM 
in combination with antibiotic-free media (corresponding to the cells being transfected). 
The plasmid containing pre-miR-124-1 and its backbone vector pEZX-MR03 were 
purchased from GeneCopoeia.  
 
For the NR4A1 and miR-124 co-transfection assay, Daoy cells were seeded at a 
density of 100,000 cells per well in a 6-well BD Falcon plate. After 24 hours, cells were 
transfected with 1 µg NR4A1 with or without its 3ʹUTR. Cells were transfected with 2.5 
µg miR-124 or its control vector (MR03) 24 hours later and collected for Western blot 
analysis 48 hours after that.   
 
For NR4A1-knockdown assays, Daoy cells were seeded at a density of 250,000 
cells in T25 flasks. Once the cells were 60%-70% confluent, they were transfected with 
20 nM siNR4A1 by using Dharmacon siGENOME siRNA (GE Healthcare, Lafayette, 
CO) and 8 μL of RNAiMAX. After 48 hours, cells were reseeded for viability and 
proliferation assays. The SMARTpool siNR4A1 (Catalog # M-003426-04) and the 
individual siNR4A1 (Catalog # D-003426-23) were both used as indicated in the figure 
legends. Non-targeting siRNA #4 (Catalog # D-001210-04-20) was used as a control for 
both the pooled and individual siRNAs.  
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Molecular cloning 
 
NR4A1 cDNA was cloned into the pEXM12-3XFLAG (N-terminal) vector 
(GeneCopoeia). Forward (5ʹ– ATACTAGTCCACCATGGACTACAAAGACC –3ʹ) and 
reverse (5ʹ– ATG AAT TCC TAG AAG GGC AGC GTG TC –3ʹ) primers were used to 
PCR-amplify 3XFLAG-NR4A1 cDNA from the pEXM12-3XFLAG-NR4A1 vector. The 
NR4A1 PCR product was then cloned into the pCR2.1 TOPO vector by using the TOPO 
TA Cloning Kit (Life Technologies). The product was then digested by using SpeI and 
EcoRI restriction enzymes (New England BioLabs, Ipswich, MA) and ligated into a 
pSIN-EF2-IRES-Blast lentiviral expression vector to generate pSIN-NR4A1. The pSIN 
vector originated from Addgene (Plasmid #16578, [460]) but was modified by inserting 
additional enzyme sites and the BlastR gene (for resistance to blasticidin).  
 
To generate a pSIN-NR4A1-3ʹUTR construct, the 3ʹUTR of NR4A1 was cloned 
from the NR4A1-3ʹUTR reporter plasmid (GeneCopoeia) and inserted into the 3ʹUTR 
region downstream of the NR4A1 coding sequence in the pSIN-NR4A1 vector. Briefly, 
the 3ʹUTR sequence was amplified by using forward (5ʹ– 
ATGAATTCCCCCTGCCTGGGAA –3ʹ) and reverse (5ʹ– 
ATGGATCCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCCAACTACATGT –3ʹ) 
primers. This 3ʹUTR PCR insert was electrophoresed on a gel, and the band was gel-
purified by using the Qiagen gel extraction kit. The purified 3ʹUTR insert was then 
cloned into the pCR2.1 TOPO vector (Life Technologies). The TOPO and pSIN plasmids 
were digested by using EcoRI and BamHI (New England BioLabs), and the 3ʹUTR 
segment was ligated into the pSIN-NR4A1 vector. All primers were synthesized by 
Invitrogen; all PCR amplifications were performed by using the Phusion High-Fidelity 
PCR Master Mix with HF Buffer (New England BioLabs); and the sequences of all final 
DNA constructs were confirmed by performing Sanger sequencing. 
 
 
Protein isolation and Western blot analysis 
 
Cells were incubated with Pierce RIPA lysis buffer (Thermo Fisher Scientific, 
Grand Island, NY) on ice for 20 minutes and centrifuged at 17,500 g for 20 minutes. The 
supernatant was collected, and its protein concentration was measured by using a Pierce 
BCA Protein Assay kit. Absorbance at 540 nM was measured by using the SpectraMax 
M5 microplate reader (Molecular Devices, Sunnyvale, CA). The protein was mixed with 
10X loading buffer and 4X LDS (Life Technologies), incubated at 95°C for 5 minutes, 
and loaded into a NuPAGE 4-12% Bis-Tris gel (Life Technologies). The separated 
protein was then transferred to a nitrocellulose membrane by using an iBlot transfer 
system (Invitrogen). The blot was blocked at room temperature for one hour by using 
Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE). Mouse monoclonal anti-
Flag M2 (Sigma; catalog # F1804-5MG; used at 1:1500 dilution) and mouse monoclonal 
anti-β-actin (Sigma; A5441; used at 1:2000 dilution) antibodies were added and 
incubated overnight at 4°C. After the primary antibodies were removed, the blot was 
washed three times with TBST for 15 minutes each time before being incubated with the 
secondary antibody for 1 hour at room temperature. After 1 hour, the blot was washed 
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three times, and proteins were detected by using the Odyssey imaging system (LI-COR 
Biosciences). ImageJ [461] was used to measure band intensity. 
 
 
Lentivirus production and transduction  
 
Two million 293T cells were seeded into each 10-cm dish. Once the cells reached 
approximately 90% confluence, they were transfected with 12 μg of the expression 
plasmid, 3 μg of the VSV-G envelope-expressing plasmid pMD2.G (Addgene, Plasmid 
#12259), and 6 μg of the 2nd-generation lentiviral packaging plasmid psPAX2 (Addgene, 
Plasmid #12260) by using 60 μL FuGENE6 (Promega) in OptiMEM. Media were 
replaced with fresh media 24 hours after transfection. The lentivirus supernatant was 
collected 48 hours after media replacement and filtered through a 0.45-μM filter and 
titrated by using Lenti-X GoStix (Clontech Laboratories, Mountain View, CA). In cases 
of low titer, Lenti-X Concentrator (Clontech Laboratories) was used to increase the 
lentiviral titer.  
 
To exogenously express NR4A1, Daoy cells were seeded at a density of 250,000 
cells in T25 flasks. Once the cells were 60%-70% confluent, they were transduced with 
NR4A1 lentivirus; Polybrene (AmericanBio, Natick, MA) was used at 0.8 μL/mL to aid 
transduction efficiency. After 48 hours, cells were reseeded for viability and proliferation 
experiments.   
 
 
Viability assay 
 
Cells were reseeded at a density of 1000 cells per well in 96-well plates, with 5 
replicates of each condition. Cell viability was determined by using the CellTiter-Glo 
Luminescent Cell Viability Assay (Promega): cells were incubated with 100 μL of the 
reagent for 20 minutes on a shaker, covered with a dark lid. Luciferase activity was 
measured by using the EnVision 2101 Multilabel Reader (PerkinElmer) on the day the 
cells were seeded (day 0) and daily after that for 3-4 days. The day 1 through day 4 
viability measurements were normalized to that measured on day 0. The initial seeding 
density of 1000 cells per well was chosen so that cells would be close to but less than 
100% confluent by the final day.  
 
 
Crystal violet staining 
 
Cells were reseeded in 12-well plates at a concentration of 15,000 cells per well, 
with 4 replicates of each condition. After removing the media and washing with PBS, we 
fixed the cells in 4% formaldehyde (Sigma-Aldrich, St. Louis, MO) and gently rocked 
them for 10 minutes at room temperature. The formaldehyde was then removed, and the 
cells were washed twice with PBS, incubated with 1% crystal violet (Sigma-Aldrich) 
while gently rocking for 10 minutes at room temperature, and then rinsed with water until 
the water washed clear, after which 0.1% SDS was added and incubated for 10 minutes 
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while gently rocking. The absorbance of each well was then measured at 590 nm by using 
a SpectraMax M5 (Molecular Devices). Crystal violet staining was performed on the 
same day as the initial cell seeding (day 0) and daily thereafter for 3-4 days. Crystal 
violet absorbance readings measured on days 1-4 were normalized to that measured on 
day 0.  
  
 
IncuCyte proliferation assays 
 
Cells were reseeded in a 24-well plate at a concentration of 10,000 cells per well, 
with 4 replicates of each condition. Cell proliferation was monitored by using an 
IncuCyte live-cell imaging system (Essen BioScience, Ann Arbor, MI): 9 images were 
captured in each well every 12 hours. The percentage of confluent cells was calculated by 
using IncuCyte software.  
 
 
Stable cell lines 
 
Stable cell lines were prepared by plating 500,000 Daoy cells in 10-cm dishes. 
After 24 hours, cells in antibiotic-free media were transfected with 10 μg of either pEZX-
MR03 (vector control) or pEZX-MR03-miR-124 in FuGENE6 diluted in OptiMEM. The 
media were replaced with normal growth media 24 hours after transfection. The cells 
were treated with 1 μg/mL puromycin 24 hours after media replacement. Puromycin was 
added every 3 days for 2 weeks until nontransduced control cells were completely killed 
by the puromycin, after which the cells were considered to be stable. Expression of miR-
124 in the stable cells was confirmed by using a microscope to observe the GFP signal 
expressed from the vector and by performing qPCR assays to quantify the levels of miR-
124.   
 
 
3D-spheroid formation assay 
 
Parental Daoy cells and Daoy cells stably expressing miR-124 or the control 
vector (MR03) were seeded into a round-bottom 96-well plate at 3 different densities 
(288, 800, and 2500 cells/well). Media were changed every 3-4 days, and spheroid areas 
were calculated after 23 days by using the IN Cell Analyzer 6000 (GE). Viability was 
also measured on day 23 by using the CellTiter-Glo 3D Cell Viability Assay (Promega) 
according to the manufacturer’s protocol and shown as raw luminescence units (RLU). 
 
 
Cerebellar granule neuron analysis 
 
Cerebellar granule neurons (CGNs) were prepared as described [462]. Briefly, 
cerebella were dissected from the brains of P7 C57BL/6 mice, and pial layers were 
removed; the tissue was treated with trypsin/DNase and triturated into a single-cell 
suspension by using fine-bore Pasteur pipettes. The suspension was layered onto a 
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discontinuous Percoll gradient and separated by centrifugation. The small-cell fraction 
was then isolated. The resulting cultures routinely contained 95% CGNs and 5% glia. 
The cultures were maintained in Basal Medium Eagle (BME; Life Technologies) 
supplemented with glutamine and 10% horse serum. All animal experiments were 
performed in accordance with a protocol approved by St. Jude Children’s Research 
Hospital’s Institutional Animal Care and Use Committee. The animals were housed at 
22−23ºC with a 12 h light/dark cycle and free access to food and water at the St. Jude 
Animal Resources Center certified by the American Association for Accreditation of 
Laboratory Animal Care. Animals were euthanized by decapitation for the preparation of 
CGNs. 
 
 
Statistical analysis 
 
Results are shown as the mean ± standard error of the mean. The sample values 
were compared to control values by using a two-tailed unpaired student’s t-test. 
GraphPad Prism 6 software was used to graph results and to calculate the statistical 
significance.  
 
 
Results 
 
 
Three miRNAs directly target NR4A1 
 
To identify miRNAs that may target NR4A1, we used a luciferase reporter system 
in which 293T cells were co-transfected with a reporter plasmid containing the 3ʹUTR of 
NR4A1 along with our collection of 296 miRNAs. In the NR4A1-3ʹUTR-Luc reporter, 
the firefly luciferase gene is directly upstream of the 3ʹUTR sequence: a miRNA that 
binds to the 3ʹUTR will decrease the translation of the luciferase mRNA, resulting in 
decreased luciferase activity being detected by the Dual-Glo Luciferase Assay System. 
As shown in a waterfall plot (Figure 3-1A), miR-124 caused the greatest reduction in 
luciferase levels among the 296 miRNAs tested. We selected 40 miRNAs that caused 
40% or more reduction in luciferase activity and retested them in triplicate: 13 of the 40 
miRNAs repeatedly decreased luciferase levels by 30% or more (Figure 3-1B).  
 
In addition to using the luciferase reporter system, we used the Cancer miRNAs 
Transcriptome PCR Array (as described in Materials and Methods), which contains 
cDNA from HeLa cells transfected with one of 90 cancer-related miRNAs, many of 
which were included in our collection of 296 miRNAs used in the luciferase reporter 
screen. We found that miR-124 was one of the 3 miRNAs that substantially 
downregulated NR4A1 (Figure A-1).  
 
Among the miRNAs that downregulated NR4A1 (Figure 3-1A and B), only miR-
124, miR-15a, and miR-224 were predicted by multiple prediction algorithms to target 
NR4A1 by binding to its seed region (a 5- to 8-nucleotide sequence within the 3ʹUTR that  
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Figure 3-1. miR-124, miR-15a, and miR-224 directly target NR4A1. 
(A) miR-124 caused the greatest decrease in luciferase activity after 293T cells were 
transfected with a NR4A1-3ʹUTR-Luc reporter and one of 296 miRNAs. Each data point 
on the waterfall plot corresponds to the resulting luciferase activity for each miRNA. 
Renilla luciferase (RLuc) was used to normalize firefly luciferase (FLuc) activity. (B) 
Thirteen miRNAs significantly (p < 0.001) reduced luciferase activity below that of the 
pSIF control vector (average of 3 independent experiments is shown). (C) The seed 
region where miR-124, miR-15a, and miR-224 are predicted to bind within the 3ʹUTR of 
NR4A1 was mutated, and luciferase assays were performed to show direct targeting of 
NR4A1 by these 3 miRNAs. The data shown are the average of 3 independent 
experiments. * indicates p < 0.001.  
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mediates the direct binding of a miRNA). These binding predictions are based on the 
predicted seed regions found within the TargetScan database. When we mutated the 
binding sites within the 3ʹUTR corresponding to seed regions for miR-124, miR-15a, and 
miR-224, the mutated 3ʹUTR (124mut, 15mut, and 224mut) became resistant to the 
corresponding miRNA (Figure 3-1C), demonstrating that these miRNAs directly target 
NR4A1 by binding to a seed region within the NR4A1 3ʹUTR. 
 
 
NR4A1 is upregulated in pediatric cancer cell lines 
 
To further investigate the functional relationship between NR4A1 and its miRNA 
regulators, we first analyzed the endogenous NR4A1 mRNA levels in several pediatric 
cancer cell lines. These levels were significantly higher in rhabdomyosarcoma cells lines 
RD, Rh41, and Rh30 than in LHCN-M2 immortalized myoblasts (Figure 3-2A). In 
addition, NR4A1 expression in D341 and Daoy medulloblastoma cells and in NB3 
neuroblastoma cells was upregulated compared to that of HCN-2 human cortical neurons 
(Figure 3-2B). We further analyzed the endogenous expression of miR-124, miR-15a, 
and miR-224 in Rh30, Daoy, and NB3 cells. As shown in Fig 2C, all 3 miRNAs were 
downregulated in Daoy, and miR-224 was decreased in NB3 cells. Interestingly, miR-124 
was upregulated in NB3, a MYCN-amplified neuroblastoma cell line [457], which is 
consistent with a recent report showing miR-124 upregulation in MYCN-amplified 
neuroblastoma when compared to nine other pediatric solid tumors including 
rhabdomyosarcoma and non-MYCN-amplified neuroblastoma [463]. The mechanism 
responsible for the upregulation of miR-124 in NB3 cells is unclear. miR-224 was 
significantly downregulated in NB3 cells (Figure 3-2C), possibly contributing to the 
upregulation of NR4A1 (Figure 3-2B). For the remainder of this study, we focused on the 
relationship between miR-124 and NR4A1 in Daoy cells because miR-124 is highly 
expressed in the brain [464] and it acts as a tumor suppressor in medulloblastoma [465-
467]. Furthermore, in undifferentiated granule neuron precursors (GNPs), the level of 
Nr4a1 was high but that of miR-124 was low (Figure A-2). Interestingly, once these 
GNPs differentiated, Nr4a1 was downregulated and miR-124 was upregulated  
(Figure A-2). These observations led us to further investigate the functional relationship 
between miR-124 and NR4A1. 
 
 
miR-124 decreases NR4A1 expression  
 
Compared to expression in HCN-2 cells, NR4A1 was upregulated and miR-124 
was downregulated in Daoy cells (Figure 3-3A). We further investigated the inverse 
correlation between NR4A1 and miR-124 expression by determining the effect of 
modulating miR-124 levels on the levels of NR4A1. As shown in Fig 3B, higher levels of 
miR-124 correlated with lower levels of NR4A1. Additionally, the NR4A1 3ʹUTR-Luc 
activity increased after treatment with a miR-124 inhibitor, further validating the inverse 
relationship between miR-124 and NR4A1 (Figure 3-3C). Another miR-124 inhibitor 
(from Exiqon) was used, yielding similar results (Figure A-3). Exogenous 
overexpression of miR-124 decreased the mRNA level of endogenous NR4A1 and that of  
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Figure 3-2. NR4A1 is upregulated in pediatric cancer cell lines. 
(A, B) NR4A1 mRNA expression is upregulated in rhabdomyosarcoma, 
medulloblastoma, and neuroblastoma cell lines. Fold-change was calculated by 
normalizing the mRNA expression levels to those of their respective control cell lines 
(either LHCN-M2 or HCN-2), which were set to 1. (C) Endogenous miRNA expression 
in Rh30, Daoy, and NB3 cells shows that all 3 miRNAs are downregulated in Daoy cells 
and that miR-224 is downregulated in NB3 cells. RNU48 was used as an internal control. 
All data shown are the average of 3 independent experiments; *p < 0.0001.  
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Figure 3-3. miR-124 decreases NR4A1 levels. 
(A) Endogenous expression levels of miR-124 and NR4A1 were measured in Daoy cells 
and human cortical neurons (HCN-2). (B) NR4A1 and miR-124 expression are inversely 
related in Daoy cells exogenously expressing various levels of miR-124. The levels of 
NR4A1 and miR-124 changed in an inversely correlated manner. (C) Daoy cells were co-
transfected with the NR4A1-3ʹUTR reporter plasmid (NR4A1-3ʹUTR-Luc) and either an 
inhibitor of miR-124 (10 – 160 nM of oligonucleotide used as indicated) or an oligo 
control (Cntrl) from Life Technologies; resulting luciferase levels were measured. The 
data shown are representative of 3 independent experiments. (D) Either miR-124 or the 
control vector (MR03) was exogenously expressed in Daoy cells, and the resulting levels 
of miR-124 and NR4A1 were measured along with the expression of NR4A1 target genes. 
(E) Daoy cells were co-transfected with miR-124 (124) or vector control (MR03) and 
Flag-NR4A1 plasmid with (3ʹUTR) or without (NR4A1) the 3ʹUTR to confirm that miR-
124 targets the 3ʹUTR. Flag and actin protein levels were detected by Western blot and 
quantified by using ImageJ. Levels of Flag protein were first normalized to those of actin; 
then MR03-3UTR was set to 1, and all other samples were compared to this sample. The 
Western blot shown is representative of 3 independent experiments, and the bar graph 
shows the average protein fold-change from 3 experiments. * indicates p < 0.05. 
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several target genes of NR4A1, including E2F1, CCND2 (cyclin D2), BIRC5 (survivin), 
TXNDC5, CDK4, and STAT5A (Figure 3-3D). Furthermore, miR-124 overexpression 
also decreased the expression of NR4A1 target genes in 293T cells (Figure A-4). To 
demonstrate that elevated miR-124 decreases NR4A1 protein levels in a 3ʹUTR-
dependent manner we examined the effect of overexpressed miR-124 on a Flag-tagged 
NR4A1 construct without the 3ʹUTR (NR4A1) or with the 3ʹUTR (3ʹUTR). As shown in  
Figure 3-3E, overexpression of miR-124 decreased the level of Flag-NR4A1 only when 
the 3ʹUTR of NR4A1 was present. 
 
 
NR4A1 promotes cell viability and proliferation 
 
Studies have shown that NR4A1 increases cell survival and proliferation in 
various adult cancer cell lines, suggesting an oncogenic role for NR4A1 in those 
particular cancers [230, 233, 239, 468-470]. We examined whether this was also the case 
for pediatric cancer cell lines, specifically Daoy medulloblastoma cells. Upon exogenous 
overexpression of NR4A1 in Daoy cells, there was increased cell viability as assessed by 
the CellTiter-Glo assay (Figure 3-4A). Cell proliferation was measured by performing 
crystal violet staining and using an IncuCyte live-cell imaging system, which monitors 
real-time cell proliferation. Compared to cells transduced with the empty vector (EV), the 
cells exogenously overexpressing NR4A1 showed increased crystal violet staining and 
confluence over the course of 4 days (Figure 3-4B and C). Figure 3-4D shows the 
elevated NR4A1 mRNA levels after transduction with NR4A1. These data support the 
notion that NR4A1 promotes tumor growth not only in adult cancers but also in pediatric 
solid tumors. 
 
 
Knockdown of NR4A1 decreases cell viability and proliferation 
 
To further validate the effects of NR4A1 on cell proliferation and viability, 
NR4A1 was knocked down via pooled siRNA targeting NR4A1 (siNR4A1). Daoy cells 
transfected with siNR4A1 exhibited decreased cell viability and proliferation as measured 
by the CellTiter-Glo assay, crystal violet staining, and the IncuCyte assay  
(Figure 3-5A-C and E). Figure 3-5D shows the knockdown efficiency. The 4 individual 
siRNAs making up the pooled siRNA were then tested individually. siNR4A1_4 most 
efficiently knocked down NR4A1 and caused the greatest decrease in cell viability and 
proliferation (Figure A-5). 
 
 
miR-124 decreases cell viability and proliferation 
 
The observations that NR4A1 promoted cell proliferation (Figures 3-4 and 3-5) 
and that miR-124 directly targeted and downregulated NR4A1 (Figure 3-3) led us to 
examine the effects of miR-124 on cell viability and proliferation. Exogenous and stable 
expression of miR-124 in Daoy cells substantially reduced cell viability and proliferation 
(Figure 3-6A-C). To measure the ability of the Daoy cells to form microtumors, we used   
 51 
 
 
 
Figure 3-4. NR4A1 promotes cell viability and proliferation. 
(A) Daoy cells were transduced with pSIN-NR4A1 (NR4A1) or pSIN vector (EV), and 
cell viability was measured via the CellTiter-Glo assay every day for 4 days. Viability for 
each day was normalized to that of Day 0 (0 hours), and statistical significance was 
calculated for each day. (B) Cells were stained with crystal violet every day for 4 days to 
measure proliferation over time. The absorbance was measured and normalized to that of 
Day 0 (0 hours). The statistical significance was calculated for each day. (C) Cell 
proliferation was monitored by using an IncuCyte live-cell imager for real-time imaging. 
The resulting cell confluence was recorded every 12 hours for 4 days. (D) NR4A1 mRNA 
level was measured after transduction with NR4A1. All experiments were performed by 
using Daoy cells transduced with EV or NR4A1 lentivirus. All data shown are 
representative of 3 independent experiments; *p ≤ 0.0001. 
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Figure 3-5. NR4A1 knockdown decreases cell viability and proliferation. 
(A) Daoy cells were transfected with 20 nM of the SMARTpool siNR4A1 or non-
targeting control (NT), and cell viability was measured via the CellTiter-Glo assay every 
day for 3 days. Viability for each day was normalized to that of Day 0 (0 hours), and 
statistical significance was calculated for each day; *p < 0.0001. (B) Cells were stained 
with crystal violet every day for 3 days to measure proliferation over time. The 
absorbance was measured and normalized to that of Day 0 (0 hours). The statistical 
significance was calculated for each day; *p < 0.01. (C) Proliferation was monitored via 
the IncuCyte live-cell imager. Cell confluence was averaged, with 4 replicates of each 
condition; *p < 0.0001. (D) NR4A1 was significantly (p < 0.0001) decreased after 
transfecting Daoy cells with siNR4A1. (E) Images shown for each NT and siNR4A1 
panel over 5 days are the same image view within the same well and are representative of 
3 independent experiments with 4 wells for each condition. These images correspond to 
the data in C. Data shown in A are representative of 5 independent experiments; data in B 
are representative of 4 independent experiments, and data in C and E are representative of 
2 independent experiments. Data shown in D is the average of 4 independent 
experiments.  
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Figure 3-6. miR-124 decreases cell proliferation in 2D and 3D cultures. 
(A) Expression of miR-124 was significantly (p < 0.0001) increased after antibiotic 
selection of Daoy cells transduced with pEZX-MR03-miR-124. As a result, NR4A1 
mRNA levels were significantly decreased (p < 0.0001). Data shown are the average of 6 
independent experiments. (B) The CellTiter-Glo assay was used to analyze the cell 
viability of Daoy cells stably expressing exogenous miR-124 or vector control (MR03). 
Viability for each day was normalized to that of Day 0 (0 hours), and statistical 
significance was calculated for each day; *p < 0.0001. (C) Stable cells were imaged by 
using the IncuCyte live-cell imager to determine cell proliferation over the course of 3.5 
days, and statistical significance was determined for each day; *p < 0.0001. (D) Parental 
Daoy cells (Daoy) and Daoy cells stably expressing exogenous miR-124 (miR-124) or its 
control vector (MR03) were seeded at 3 densities (288, 800, and 2500 cells/well) and 
grown using 3D culture techniques. After 23 days (left panel), the cells’ spheroid areas 
(*p < 0.01) were measured by using the IN Cell Analyzer (middle panel). Viability 
(*p < 0.05) was determined by performing CellTiter-Glo 3D Cell Viability Assays and is 
shown as raw luminescence units (RLU) (right panel). The spheroid area data shown are 
for cells seeded at an initial density of 800 cells per well. Data from B are representative 
of 5 independent experiments; data from C are representative of 4 independent 
experiments, and data from D are representative of 2 independent experiments. 
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round-bottom 96-well plates to promote the formation of 3D spheroids. After allowing 
the cells to form spheroids for 23 days, we found that cells exogenously overexpressing 
miR-124 underwent less spheroid growth and viability than did the control cells (Figure 
3-6D). These results are consistent with previously reported evidence showing the 
negative effects of miR-124 on medulloblastoma cell growth [465-467]. 
 
 
Conclusions 
 
To our knowledge, our study is the first to show that the level of NR4A1 is 
regulated by miR-124 and that NR4A1 has roles in proliferation of pediatric cancer cells 
such as Daoy medulloblastoma cells. Most published research on NR4A1 as a therapeutic 
target involves using drugs to induce NR4A1-mediated apoptosis; our discovery that 
miR-124 regulates NR4A1 suggests that it may be possible to modulate NR4A1 and 
influence cancer cell growth by regulating miR-124. 
 
In a panel of pediatric cancer cell lines, we found NR4A1 to be upregulated in all 
cell types including RD, Rh41, and Rh30 RMS cells, D341 and Daoy medulloblastoma 
cells, and NB3 neuroblastoma cells. We identified 3 miRNAs that directly target NR4A1, 
including miR-124, miR-15a, and miR-224, all of which were downregulated in Daoy, 
demonstrating an inverse correlation between NR4A1 and the miRNAs that target it. 
However, we did not observe this trend in the other cell types. There are most likely 
additional miRNAs that target NR4A1 in the other cell types and perhaps this is why we 
did not see a correlation.  
 
It is difficult to conclusively determine the role of NR4A1 in medulloblastoma 
based on these studies as Daoy cells are not classified as any of the 4 subtypes of 
medulloblastoma. Furthermore, there is not substantial evidence in expression databases 
demonstrating whether or not NR4A1 is upregulated in patients with medulloblastoma. 
Therefore, further studies showing expression levels of NR4A1 in medulloblastoma are 
required in order to make this determination. Furthermore, tumorigenicity assays such as 
soft agar colony formation assays that test anchorage independent growth can be 
performed in multiple medulloblastoma cell types that more closely resemble the 
different subtypes of medulloblastoma. The tumorigenic potential of NR4A1 can also be 
tested in vivo wherein NR4A1 can be overexpressed in a medulloblastoma cell line that is 
then injected into mice and the resulting tumors are measured to determine if NR4A1 
promotes the growth of medulloblastoma tumors. Additionally, knockdown studies can 
be conducted in vivo to conclusively confirm whether or not NR4A1 affects the growth 
rate of medulloblastoma tumors.    
Interestingly, we found that NR4A1 expression decreases while miR-124 
expression increases in differentiating GNPs. This supports previous research showing 
that miR-124 expression is higher in differentiated GNPs compared to undifferentiated 
GNPs. The decrease in NR4A1 expression suggests that NR4A1 must be downregulated, 
possibly by miR-124, in order for differentiation to occur. It is of interest to explore the 
function of NR4A1 in GNPs as these are the main type of neuron in the cerebellum where 
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a subtype of medulloblastoma originates. A more thorough discussion on this topic can 
be found in Chapter 5. 
In short, we found that miR-124 targets and decreases NR4A1 expression and 
function. NR4A1 promotes cell proliferation in Daoy medulloblastoma cells, but miR-
124 reduces it, in part by targeting NR4A1 and decreasing its transcriptional activity. This 
results in decreased expression of NR4A1 target genes important in cell cycle progression 
and survival. This study supports the use of miRNA mimics to treat cancers, especially 
those in which NR4A1 has an oncogenic role.  
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CHAPTER 4.    THE ROLE OF NR4A1 IN SKELETAL MUSCLE 
DIFFERENTIATION 
 
 
Introduction 
 
Diseases related to muscle such as Duchenne muscular dystrophy and 
rhabdomyosarcoma, which are prevalent in children, are in desperate need of effective 
treatments. In order to develop therapies, it is critical to understand normal muscle 
development and function. The process of muscle formation, termed myogenesis, 
involves several stages including proliferation, migration, and differentiation. During the 
first stage, mesodermal progenitors exit the cell cycle and several transcription factors 
appear including Pax3, Pax7, Myf5, and MyoD1. These transcription factors are required 
for the cells to become myoblasts. These myoblasts will then align with one another and 
become myocytes after the expression of additional transcription factors including 
myogenin (MYOG) and Myf6. During the final stages of differentiation, the myocytes 
will fuse to form multinucleated myotubes, which will then become muscle fibers. 
Additional muscle markers such as myosin heavy chain (MHC/MYH) and muscle 
creatine kinase (CKM) become expressed in the later stages of differentiation [471-473]. 
 
NR4A1 has many physiological roles in various tissues such as its involvement in 
muscle function. For example, Nr4a1 promotes glucose and oxidative metabolism in 
skeletal muscle and has even been shown to promote myofiber size and muscle mass in 
mice [148, 474, 475]. However, the role of NR4A1 during human skeletal muscle 
differentiation is not well understood. For these studies, we utilized primary SkMC and 
HSMM as well as immortalized LHCN human skeletal muscle cells. In this study we 
found that NR4A1 expression increases during the myogenic program in LHCN, and 
knockdown of NR4A1 results in decreased expression of myogenic markers in all 3 cell 
types. This suggests that NR4A1 participates in skeletal muscle differentiation. 
 
In addition, ZNF148 may regulate NR4A1 during myogenesis by suppressing its 
expression. Knockdown of ZNF148 in LHCN rapidly induced the formation of myotubes 
with a resulting increase in NR4A1 expression. Understanding these mechanisms may be 
beneficial in cancer since certain malignancies such as rhabdomyosarcoma result from 
the failure of cells to differentiate and instead proliferate uncontrollably, leading to tumor 
formation and cancer progression.  
 
 
Methods 
 
 
Cell culture 
 
LHCN-M2 (LHCN) cells are human skeletal myoblasts [458] and were grown in 
flasks coated with extracellular matrix (0.2% MaxGel ECM in PBS from Sigma-Aldrich) 
and cultured in DMEM supplemented with 15% FBS, 0.02M HEPES, 0.03 µg/mL zinc 
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sulfate, 1.4 µg/mL vitamin B12, 0.055 µg/mL dexamethasone, 2.5ng/mL hepatocyte 
growth factor (recombinant human), 10 ng/mL basic fibroblast growth factor, and 1% 
penicillin-streptomycin (Life Technologies, Carlsbad, CA). Differentiation was induced 
by the addition of differentiation media, which consisted of DMEM supplemented with 
0.02M HEPES, 0.03 µg/mL zinc sulfate, 1.4 µg/mL vitamin B12, 10 µg/mL insulin, 100 
µg/mL apo-transferrin, and 1% penicillin-streptomycin. Human skeletal muscle cells 
(SkMC) and myoblasts (HSMM) were purchased from Lonza (Walkersville, MD) and 
originate from gestational tissue and adult tissue, respectively. They were cultured in 
SkGM-2 Skeletal Muscle Cell Growth Medium-2 (BulletKit from Lonza) and were 
differentiated by adding 2% horse serum to DMEM/F-12 media (Lonza). All cells were 
cultured at 37°C in 5% CO2. 
 
 
Transfection 
 
LHCN were plated at 100k cells/well in 6-well plates coated with ECM. After 24 
hours they were transfected with 10 nM non-targeting control (NT) or siRNA for NR4A1 
(siNR4A1) and 5 ul RNAiMAX (in 300 ul of OptiMEM). Media was replaced with fresh 
media 24 hours after transfection. Differentiation media was added once the cells reached 
100% confluence, which was typically 72 hours post-transfection. Media was replaced 
every 2 days during the course of differentiation. For knockdown of ZNF148, cells were 
transfected with 10 nm control (Cntrl) or siZNF148 (Cat. # D-012658-04). Reagents for 
siRNA were purchased from Dharmacon using their siGENOME siRNA (GE Healthcare, 
Lafayette, CO). For both siNR4A1 and siZNF148, the knockdown efficiency was 
approximately 90%, and 3 out of 4 of the individual siRNAs had a similar phenotype, 
indicating that they are specific to their respective target genes. SkMC and HSMM were 
plated at 150k cells/well in 6-well plates and were transfected 48 hours after plating. 
Once cells reached 70-80% confluence, differentiation was induced by the addition of 
differentiation media, which was replaced every 2 days.  
 
  
RNA extraction and qPCR 
 
RNA was extracted by using the Maxwell 16 LEV simplyRNA Tissue Kit in 
conjunction with the Maxwell 16 Research Instrument (Promega). The resulting RNA 
concentration was measured by using the NanoDrop and was subsequently converted to 
cDNA by using the SuperScript VILO cDNA Synthesis Kit (Life Technologies). Target 
gene mRNA expression was detected by using specific Taqman probes (20X) and 
quantitated via the 7900HT Fast Real-Time PCR System (Applied Biosystems). 18S 
(Assay ID Hs99999901_s1) was used as an endogenous control for all gene expression 
analysis, including NR4A1 (Assay ID Hs00374226_m1), MYOG (Assay ID 
Hs01072232_m1), MYH2 (Assay ID Hs00430042_m1), CKM (Assay ID 
Hs00176490_m1), and ZNF148 (Assay ID Hs01070570_m1).  
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Protein isolation and Western blot analysis 
 
Cell pellets were lysed in Pierce RIPA lysis buffer (Thermo Fisher Scientific, 
Grand Island, NY) and incubated on ice for 30 minutes prior to sonication for 5 s and 
finally centrifugation at 17,500 g for 5 minutes. The protein concentration was measured 
by using a Pierce BCA Protein Assay kit and absorbance was measured at 540 nM by 
using the SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA). The 
protein lysate was mixed with 10X loading buffer and 4X LDS (Life Technologies) and 
incubated at 95°C for 5 minutes. Subsequently, the protein mixture was loaded into a 
NuPAGE 4-12% Bis-Tris gel (Life Technologies) and run at 100 V for 2 hours. The 
protein was then transferred to a PDVF membrane using the slow transfer method. This 
method involves activation of the PDVF membrane with methanol for 10 minutes 
followed by incubation in transfer buffer to remove the methanol. The protein was 
transferred to the PDVF membrane overnight on ice at 0.45 amperes. The blot was then 
blocked at room temperature for one hour by using Odyssey blocking buffer (LI-COR 
Biosciences, Lincoln, NE). Mouse monoclonal anti-MHC (produced using hybridoma 
cells from the Developmental Studies Hybridoma Bank; used at 1:200 dilution), mouse 
monoclonal anti-myogenin (Santa Cruz; used at 1:500), and mouse monoclonal anti-β-
actin (Sigma; A5441; used at 1:2000 dilution) antibodies were added and incubated 
overnight at 4°C. After the primary antibodies were removed, the blot was washed with 
TBST three times for 15 minutes each time prior to incubation with the secondary 
antibody (LI-COR Biosciences; used at 1:10,000 dilution) for 1 hour at room 
temperature. Subsequently, the blot was washed three times with TBST and proteins were 
detected by using the Odyssey imaging system (LI-COR Biosciences).  
 
 
Immunofluorescence 
 
Cells were washed 3 times with PBS and fixed with 2% paraformaldehyde for 15 
minutes at room temperature followed by additional washes with PBS. The cells were 
then permeabilized with 0.1% Triton X-100 for 15 minutes followed by 3 washes with 
PBS. The monolayer was then washed 5 times with 0.5% BSA diluted with PBS (PBB) 
and blocked with 2% BSA for 45 minutes followed by 5 washes with PBB. The primary 
antibody for myosin heavy chain 1 (MHC) was added at a 1:100 dilution overnight at 4°C 
and then washed 5 times with PBB. The secondary antibody was used at a 1:500 dilution 
and incubated for 1 hour at room temperature followed by 5 washes with PBB. DAPI was 
added at a 30,000 dilution of 1mg/ml for 5 minutes followed by 5 washes with cold PBS. 
The chambers were then removed and mounted with coverslips and mounting media and 
imaged using a Nikon Eclipse Ti microscope.  
 
  
Statistical analysis 
 
Results are shown as the mean ± standard error of the mean. Significance was 
determined by using a two-tailed unpaired student’s t-test to compare the sample values 
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to the control values. GraphPad Prism 6 software was used to graph results and to 
calculate the statistical significance. 
  
 
Results 
 
 
NR4A1 expression increases during LHCN myogenesis 
 
To determine if NR4A1 plays a role during myogenesis, expression was analyzed 
during the differentiation of LHCN, SkMC, and HSMM human skeletal muscle cells. 
NR4A1 mRNA levels increased by about 4 fold during the differentiation of LHCN, 
however it did not substantially increase in SkMC and HSMM cells. To verify that the 
cells were indeed differentiated, the myogenic markers MYOG, MYH2, and CKM were 
measured (Figures 4-1, 4-2, and 4-3). MYOG is considered an early marker whereas 
MYH2 and CKM are late differentiation markers. In order to determine if the other 
NR4A family members are playing a role, the mRNA levels of NR4A2 and NR4A3 were 
measured in all 3 cell types. NR4A2 was greatly decreased in LHCN and SkMC but not in 
HSMM, whereas NR4A3 was increased in all 3 cell types. This suggests that NR4A2 may 
inhibit differentiation while NR4A3 may promote it.   
 
 
NR4A1 knockdown delays differentiation 
 
To determine the significance of the increased NR4A1 expression in LHCN, 
NR4A1was knocked down via siRNA (siNR4A1). As a result, differentiation was 
severely delayed as shown by the decrease in differentiation markers and the visible lack 
of myotube formation (Figure 4-4B-D). Protein levels for MYOG and MHC were also 
extremely decreased in the cells lacking NR4A1 (Figure 4-4E). Bright-field images of the 
cells clearly show well-differentiated NT cells by Day 4 compared to the siNR4A1 cells 
that did not form myotubes (Figure 4-4F). Interestingly, NR4A1 expression was induced 
up to 15 fold by Day 5 in the cells transfected with the non-targeting (NT) control 
(Figure 4-4A). This is a much larger induction compared to the untransfected LHCN in 
Figure 4-1A. Similar results were observed in SkMC and HSMM, however the NR4A1 
mRNA levels actually decreased during differentiation in the NT cells  
(Figures 4-5 and 4-6).   
 
 
ZNF148 knockdown induces differentiation 
 
Studies from our lab have demonstrated that knockdown of the transcription 
factor ZNF148 rapidly induces differentiation in LHCN cells, suggesting that ZNF148 
plays an inhibitory role during myogenesis. One study has shown that ZNF148 can 
suppress the expression of NR4A1 by directly binding to its promoter [446]. To determine 
the functional significance of this inhibitory mechanism, ZNF148 was knocked down via 
siRNA in LHCN cells which resulted in the rapid formation of myotubes by Day 2   
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Figure 4-1. NR4A1 expression increases during LHCN differentiation. 
(A-F) LHCN were differentiated for 5 days with cells collected for each day beginning 
on Day 0 when differentiation media is added. The mRNA levels for NR4A1, NR4A2, 
NR4A3, myogenin (MYOG), myosin heavy chain (MYH2), and muscle creatine kinase 
(CKM) were measured and normalized to Day 0, which was set to 1. Data shown is the 
average of at least 2 independent experiments. * indicates p < 0.01. 
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Figure 4-2. NR4A1 expression does not increase during SkMC differentiation. 
(A-F) SkMC were differentiated for 5 days with cells collected every day beginning on 
Day 0 when differentiation media was first added. The mRNA levels of NR4A1, NR4A2, 
NR4A3, MYOG, MYH2, and CKM were measured and normalized to Day 0, which was 
set to 1. Data shown is the average of 5 independent experiments. * indicates p < 0.05. 
 62 
 
 
Figure 4-3. NR4A1 expression does not increase during HSMM differentiation. 
(A-F) HSMM were differentiated for 5 days with cells collected every day beginning on 
Day 0 when differentiation media was first added. The mRNA levels of NR4A1, NR4A2, 
NR4A3, MYOG, MYH2, and CKM were measured and normalized to Day 0, which was 
set to 1. Data shown is the average of at least 2 independent experiments. * indicates 
p < 0.05. 
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Figure 4-4. Knockdown of NR4A1 delays differentiation in LHCN. 
(A-D) LHCN were transfected with 10 nm non-targeting control (NT) and siRNA for 
NR4A1 (siNR4A1) prior to differentiation for 5 days with cells collected every day 
beginning on Day 0. The mRNA levels of NR4A1 and differentiation markers were 
measure and normalized to NT Day 0, which was set to 1. Data shown is the average of 3 
independent experiments. (E) Protein levels for MHC, MYOG, and β-actin were detected 
in a western blot. (F) Bright-field images with 10X magnification were taken on Days 0, 
2, and 4 with representative images shown. 
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Figure 4-5. NR4A1 knockdown delays differentiation in SkMC. 
(A-D) SkMC were transfected with 10 nm NT and siNR4A1 prior to differentiation for 5 
days. The mRNA levels of NR4A1 and differentiation markers were measured and 
normalized to NT Day 0, which was set to 1. Data shown is the average of 3 independent 
experiments. (E) Protein levels of MYOG and β-actin were measured in a western blot. 
(F) Bright-field images at 10X magnification were taken on Days 0, 3, and 5 with 
representative images shown. 
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Figure 4-6. NR4A1 knockdown delays differentiation in HSMM. 
(A-D) HSMM were transfected with 10 nm NT and siNR4A1 prior to differentiation for 
5 days. The mRNA levels of NR4A1 and differentiation markers were measured and 
normalized to NT Day 0, which was set to 1. Data shown is the average of 2 independent 
experiments. 
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(Figure 4-7C-D). Interestingly, knockdown of ZNF148 induced differentiation in the 
presence of growth media, demonstrating the strong repressive power of endogenous 
ZNF148 in the control cells (Figure 4-7A). Accordingly, NR4A1 expression was also 
induced more than 15 fold in the cells with siZNF148 under growth conditions and more 
than 10 fold under differentiation conditions (Figure 4-7B).   
 
 
Conclusions 
 
In all, we discovered a novel role for NR4A1 in skeletal muscle differentiation. 
NR4A1 expression increases during the myogenic program in LHCN, and knockdown of 
NR4A1 results in decreased expression of differentiation markers in LHCN, SkMC, and 
HSMM human skeletal muscle cells. This supports a previous study showing that Nr4a1 
increases during the differentiation of mouse C2C12 skeletal muscle cells [142, 476]. 
However in that study, they noted that differentiation still occurred in the absence of 
Nr4a1. Perhaps the difference in our results depends on the species and cell type as those 
studies were conducted in murine cells whereas these studies were performed in human 
cells.   
 
Although NR4A1 was increased in LHCN, it was not increased in SkMC or 
HSMM. This could be an artifact of the immortalized state of LHCN, whereas SkMC and 
HSMM are primary cells. We would expect NR4A1 to have similar expression patterns 
in LHCN and HSMM since these two cell types both originate from adult tissue, whereas 
SkMCs are isolated from gestational tissue. Another difference in cell type is that SkMCs 
are precursors and therefore less differentiated, whereas HSMM and LHCN are 
myoblasts committed to becoming muscle. Even though NR4A1 was not increased in 
SkMC and HSMM, knockdown of NR4A1 in these cells still resulted in decreased 
expression of myogenic markers. Therefore it would appear that NR4A1 is important 
during myogenesis. It was also interesting to observe the higher induction of NR4A1 in 
cells transfected with NT. Perhaps there are some off target effects of the NT that 
inadvertently increase NR4A1 levels. It would be reasonable to test additional NT 
controls to determine if these effects are specific to the original NT used here. 
Furthermore, we found that NR4A2 was decreased during the differentiation of LHCN 
and SkMC while NR4A3 was increased in all 3 cell types. This suggests that NR4A2 
overexpression should hypothetically inhibit differentiation while NR4A3 overexpression 
should promote it. Perhaps the NR4A family has synergistic effects where myogenesis is 
enhanced upon NR4A2 knockdown and NR4A1 and NR4A2 overexpression.  
 
Since there are several stages of differentiation, it is of interest to determine the 
stage in which NR4A1 is acting. Perhaps it is promoting the initial stages of cell cycle 
arrest, or maybe it is mainly functioning during a later stage. One way to elucidate this 
would be to determine the differentiation and fusion indices. The differentiation index is 
a measure of the number of nuclei in myosin-positive cells which indicates how 
differentiated the cells are whereas the fusion index is a measure of the number of nuclei 
in each myotube, indicating the ability of myoblasts to fuse into myotubes [477]. 
Calculating these indices would help determine the effect of NR4A1 on how well the   
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Figure 4-7. Knockdown of ZNF148 rapidly induces differentiation in LHCN. 
(A-C) LHCN cells were transfected with 10 nM Cntrl or siZNF and cultured in either 
growth (G1, G3) or differentiation (D1, D3) media with cells collected on Days 1 and 
Day 3. The resulting mRNA levels of MYH2, ZNF148, and NR4A1 were measured and 
normalized to Cntrl G1, which was set to 1. (D) Immunofluorescence was performed to 
detect MHC (green) and DAPI (blue) in cells with ZNF148 knocked down. Images 
shown are 20X magnification and were taken 2 days after the addition of differentiation 
media. 
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cells are able to differentiate and fuse. It is possible that knocking down NR4A1 is 
blocking or delaying myoblast fusion without effecting differentiation.  
 
On the other hand, NR4A1 may actually be more involved in the metabolism 
aspect. Upon knockdown of NR4A1 in LHCN, SkMC, and HSMM, the muscle marker 
CKM is dramatically downregulated whereas the other muscle markers MYOG and 
MYH2 are only modestly decreased. Many studies have shown that CKM is an essential 
enzyme during energy homeostasis and mediates the synthesis of creatine phosphate 
(CrP) and ADP by transferring the gamma phosphate from ATP. During intense exercise 
when there is a high demand for energy, CKM will then synthesis ATP from CrP and 
ADP [478]. As expected, decreased CKM contributes to the gradual loss of muscle mass 
and function during aging in vivo [478, 479]. As mentioned, NR4A1 has been shown to 
promote glucose and oxidative metabolism in murine skeletal muscle [148, 474]. 
Therefore, it is quite possible that the role of NR4A1 in muscle is primarily related to 
metabolism. To confirm this, expression of additional genes involved in metabolism 
should be analyzed upon knockdown or overexpression of NR4A1 during the 
differentiation of LHCN, SkMC, and HSMM cells. 
 
Interestingly, knockdown of ZNF148 resulted in elevated levels of NR4A1 as well 
as rapid formation of myotubes, even in the absence of differentiation growth factors. 
This most likely occurs by the direct repression of NR4A1 by ZNF148 at the promoter of 
NR4A1 as previously shown in pancreatic β-cells. This demonstrates a possible 
mechanism by which ZNF148 and NR4A1 may be controlling skeletal muscle 
differentiation. These results also highlight ZNF148 as a therapeutic target in diseases 
such as RMS where the cells have failed to differentiate.  
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CHAPTER 5.    DISCUSSION* 
 
 
Regulation of NR4A1 by miRNAs in Cancer 
 
The regulation of NR4A1 by miRNAs was previously unknown, and the function 
of NR4A1 in pediatric cancers is currently undetermined. In this study, we found that 
miR-124 directly targets NR4A1 and that NR4A1 is upregulated in multiple pediatric 
cancer cell lines, including rhabdomyosarcoma, neuroblastoma, and medulloblastoma 
cell lines. We focused on elucidating the function of NR4A1 and miR-124 in 
medulloblastoma cells, and showed that exogenous expression of miR-124 in Daoy 
medulloblastoma cells decreased the cells’ proliferation and viability.  
 
Several previous reports suggest that miR-124 might also regulate NR4A1 
indirectly. In pancreatic beta-cells, Sp1 binds to the promoter of NR4A1 and increases 
NR4A1 levels [480]. Interestingly, during neuronal differentiation of mesenchymal stem 
cells, miR-124 targets Sp1 mRNA and decreases Sp1 expression [481]. The results of 
these studies suggest that miR-124 may indirectly decrease NR4A1 expression by 
decreasing Sp1. In addition, NR4A1 binds to the promoter of several target genes, 
including E2F1, CCND2 (cyclin D2), BIRC5 (survivin), TXNDC5, CDK4, and STAT5A 
[231, 233, 438, 439]. Consistent with these reports, we showed that overexpression of 
miR-124 decreased expression of these 6 target genes. By promoting expression of these 
genes, NR4A1 exerts its effects on cell proliferation and survival. Aberrant 
overexpression of NR4A1 can, therefore, lead to tumor growth and cancer progression. 
Figure 5-1 summarizes our discovery of the miR-124/NR4A1 functional relationship in 
the context of relevant previous reports. 
 
Medulloblastoma is a highly malignant primary brain tumor that originates in the 
cerebellum. It is also the most common malignant brain tumor in children, with patients 
having a 50%-80% chance of survival depending on the specific tumor type and other 
factors [482, 483]. There are 4 subgroups of medulloblastoma: Wnt, Shh, Group 3, and 
Group 4 [484]. A study profiling miRNAs in Shh MB tumors found 30 miRNAs that 
were downregulated in tumors with high Gli1, one of which was miR-124 [485]. Another 
miRNA profiling study also found that miR-124 in a Shh MB mouse model was 
downregulated compared to that in 1-month-old cerebella [486]. Furthermore, a study 
profiling 19 human medulloblastomas found that miR-124 was downregulated in the 
Wnt- and Shh-associated MBs [487]. Additionally, one study of miRNA profiles in 34 
human primary medulloblastomas found that miR-124 was downregulated (subtypes 
were not specified) [488]. 
 
 
--------------------- 
*Modified with permission from PLOS ONE. Tenga, A., et al., Regulation of Nuclear 
Receptor Nur77 by miR-124. PLOS ONE, 2016. 11(2): p. e0148433.  
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Figure 5-1. Overview of NR4A1 regulation by miR-124. 
NR4A1 can be directly targeted by miR-124, as revealed by our studies reported here 
(indicated by the red line), or indirectly affected by miR-124 via Sp1. NR4A1 may act 
through several downstream target genes to promote cell proliferation and survival. 
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Interestingly, miR-124 is the most abundant miRNA in the brain [464] and 
functions to promote neuronal differentiation [489], regulate neural stem cells [490], and 
induce differentiation in glioma stem cells [491]. Pierson et al. first showed that miR-124 
targets CDK6 in medulloblastoma cell lines and that miR-124 is downregulated in 
medulloblastoma cells lines and tumors [465]. Silber et al. went on to show that miR-124 
inhibits proliferation of medulloblastoma cells via cell-cycle arrest during G1 and that 
these results are more dramatic in cells with higher CDK6 levels. Importantly, inducible 
overexpression of miR-124 in vivo significantly reduced tumor growth generated by 
subcutaneous injection of D425 medulloblastoma cells [467]. Li et al. also found 
downregulation of miR-124 in 29 medulloblastomas and showed that miR-124 targets 
SLC16A1, which functions to efflux lactic acid during aerobic glycolysis. The authors 
suggest that inhibition of SLC16A1 by miR-124 decreases intracellular pH to a lethal 
level, leading to the observed growth inhibition in medulloblastoma cell lines upon 
overexpression of miR-124 [466]. It is clear that miR-124 has an important tumor-
suppressive role in medulloblastoma and that it acts through various target genes. Our 
research provides, for the first time, an additional target gene of miR-124, NR4A1, which 
has known oncogenic roles in adult solid tumors.  
 
As summarized in Figure 5-1, miR-124 may also indirectly downregulate NR4A1 
by directly targeting the mRNA of Sp1, resulting in reduced Sp1 and NR4A1 levels. 
Additionally, miR-124 is predicted to target CCND2 and TXNDC5, which are both target 
genes of NR4A1. Furthermore, miR-124 is predicted to target RXRA (RXRα) and GSK3B 
(GSK3β). RXRα and NR4A1 heterodimerize and either translocate to the mitochondria to 
induce apoptosis or bind to the promoters of NR4A1 target genes to modulate 
transcription [162, 175]. GSK3β suppresses NR4A1 activity by phosphorylating NR4A1 
in colorectal cancer [418]. Therefore, it is possible for miR-124 to exert both positive and 
negative effects directly and indirectly on NR4A1, depending on the specific cellular 
context. 
 
The main type of neuron that makes up the cerebellum is the granule neuron. We 
found an inverse expression pattern whereby NR4A1 is upregulated and miR-124 is 
downregulated in Daoy medulloblastoma cells and in undifferentiated murine GNPs. 
Similar to Daoy medulloblastoma cells, in undifferentiated GNPs, the level of NR4A1 is 
high and that of miR-124 is low. Once the GNPs differentiate into mature granule 
neurons, NR4A1 levels drop dramatically and miR-124 expression increases. These 
observations are consistent with those in studies showing that miR-124 promotes 
neuronal differentiation [489-491] and that miR-124 levels in 1-month-old mouse 
cerebellar tissue are higher than those in P6 GNPs [486]. The dramatic decrease in 
NR4A1 expression after differentiation suggests that the levels of NR4A1 need to be 
reduced before the cells can develop into mature neurons.  
 
It is reasonable to hypothesize that increased levels of miR-124 are needed to 
decrease NR4A1 for differentiation to occur. Aberrant downregulation of miR-124 might 
block differentiation and promote tumorigenesis, warranting the future investigation of 
the regulation of miR-124 levels. The miR-124 promoter has been reported to be 
hypermethylated in pancreatic cancer [492], hepatocellular carcinoma [493, 494], 
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ulcerative colitis, [495] and acute lymphoblastic leukemia [496]. It is therefore of interest 
to analyze the promoter of miR-124 before and after differentiation to identify any 
changes in methylation status and to identify proteins that may bind to the promoter of 
miR-124, thereby affecting endogenous levels of miR-124. 
 
NR4A1 can reportedly enhance neuronal outgrowth and differentiation: both 
dibutyryl-cAMP (dbcAMP) and trichostatin A (TSA) promote neurite outgrowth in PC12 
rat pheochromocytoma cells by inducing Nr4a1 expression via acetylated Lys14 of 
histone H3, and knockdown of Nr4a1 inhibits dbcAMP and TSA-induced neurite 
outgrowth [497, 498]. NR4A1 overexpression also promotes neurite formation in PC12 
cells [498]. However, the opposite phenotype is observed in a murine macrophage cell 
line. Oxidized low-density lipoprotein (oxLDL) induces mature macrophages to 
differentiate into dendritic cells and induces NR4A1 expression in vascular cells. 
However, when NR4A1 is overexpressed in RAW264.7 murine macrophages, 
differentiation into dendritic cells is inhibited in the presence of oxLDL [499]. This 
comes back to the key point that NR4A1 functions are heavily dependent on cellular 
context, so it is possible for NR4A1 to have opposing functions in different tissues and 
cell types.   
 
Daoy cells are classified as desmoplastic cerebellar medulloblastoma [500]; 
however, researchers have found that this cell line does not mimic any of the 4 subtypes 
of medulloblastoma. It would be useful to compare the expression level of NR4A1 in the 
brain to that in medulloblastoma tumors, but unfortunately there are not substantial 
published data showing NR4A1 levels in human medulloblastoma. However, two 
databases show low basal expression of NR4A1 in healthy cerebellum. The Brain 
Transcriptome Database shows that in situ hybridization images of the cerebellum have 
very little NR4A1 signal [501]. In addition, the Genotype-Tissue Expression project 
found that expression levels of NR4A1 in different parts of the brain, including the 
cerebellum, were much lower than those in other normal tissue types [502]. Given our 
finding of elevated NR4A1 in Daoy cells, NR4A1 may have an oncogenic role in 
medulloblastoma, which is supported by our data showing that exogenous overexpression 
of NR4A1 promotes Daoy cell viability and proliferation and that NR4A1 knockdown 
results in the opposite phenotype.  
 
Upon overexpression of miR-124 in Daoy cells, NR4A1 mRNA and protein 
levels and the mRNA levels of NR4A1 target genes decreased, showing that miR-124 
affects not only NR4A1 expression but also the transcriptional activity of NR4A1. Stable 
overexpression of miR-124 led to decreases in cell viability, cell proliferation, and 
microtumor spheroid size, suggesting therapeutic potential for miR-124 in treating 
cancer. 
 
 
Role of NR4A1 in Skeletal Muscle Differentiation 
 
NR4A1 appears to play a variety of roles in muscle, including the enhancement of 
glucose and oxidative metabolism in C2C12 mouse myoblasts and in vivo in mouse and 
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rat muscle [148, 474]. In addition, older studies have shown that Nr4a1 expression 
increases during C2C12 differentiation [142]. These cells still retained the potential to 
differentiate when Nr4a1 was knocked down, however several genes involved in lipolysis 
were decreased. This led to the conclusion that NR4A1 is important for energy 
expenditure and has potential therapeutic value in treating obesity [142]. More recently, 
NR4A1 was found to promote myofiber size and muscle mass in vivo through activation 
of the Akt-mTOR-S6K cascade [475]. After global and muscle-specific knockout of 
Nr4a1, the muscle mass was decreased. Importantly, primary myoblasts from these mice 
formed fewer and smaller myotubes [475]. The above studies were all performed using 
either animal models or murine C2C12 cells. We wanted to determine the function of 
NR4A1 during skeletal muscle differentiation using human cell lines.  
 
During the differentiation of LHCN, we found that NR4A1 expression increases 
by about 4 fold. These results are consistent with previous studies showing a 3-5 fold 
increase of Nr4a1 in C2C12 cells [142, 476]. It is of interest to determine which stage 
NR4A1 is becoming expressed. Since NR4A1 expression does not increase until Day 3 of 
differentiation, it would appear that its presence is not crucial for the initiation of 
differentiation. However when NR4A1 was knocked down via siRNA, the induction of 
differentiation was severely delayed alongside decreased expression of muscle markers in 
LHCN, SkMC, and HSMM. It is also possible that the fusion of myoblasts is being 
blocked or delayed. Thus we will need to determine exactly which stage NR4A1 is 
playing a role. Nonetheless, this suggests that NR4A1 is important during the 
differentiation of skeletal muscle cells.  
 
Previous studies in our lab have demonstrated that the zinc finger transcription 
factor ZNF148 (ZBP-89) acts as a suppressor of the myogenic program as deduced from 
knockdown studies showing rapid formation of myotubes in LHCN cells when ZNF148 
was expressed at extremely low levels. As a well-known repressor of transcription, 
ZNF148 is likely acting by binding to the promoters of genes involved in myogenesis and 
inhibiting their expression. A recent study links ZNF148 to NR4A1 by demonstrating the 
ability of ZNF148 to bind the promoter of NR4A1 and block its expression in pancreatic 
β-cells [480]. This discovery led us to question whether ZNF148 is transcriptionally 
regulating NR4A1 during skeletal muscle differentiation. Upon knockdown of ZNF148 
via siRNA in LHCN cells, NR4A1 expression was rapidly induced by 15 fold along with 
high levels of MHC. This suggests that ZNF148 represses NR4A1 in skeletal muscle cells 
and that downregulation of ZNF148 by siRNA relieves this repression. To confirm this, 
we will need to perform ChIP and probe for ZNF148 at the promoter of NR4A1 in LHCN 
cells.  
 
Furthermore, it is unclear whether NR4A1 induction is due to the knockdown of 
ZNF148 or as a result of induced differentiation. To elucidate this, we knocked down 
both ZNF148 and NR4A1 and tested whether siZNF148 was still able to induce 
differentiation. If ZNF148 functions through NR4A1, we would expect abnormal 
differentiation in the absence of NR4A1. However, we found that differentiation was still 
induced at the same rate (data not shown). Therefore, it would appear that the mechanism 
of siZNF148-mediated differentiation is not solely through NR4A1. Since ZNF148 is a 
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transcription factor and is known to target and suppress numerous genes, it may still be 
acting through NR4A1 in addition to many other genes. Therefore, knockdown of NR4A1 
alone would not be sufficient to rescue this phenotype. Another member of the NR4A 
family, NR4A3, may be compensating for the lack of NR4A1. Our study among other 
studies has shown that NR4A3 increases during skeletal muscle differentiation and 
therefore it may have redundant roles with NR4A1 [503]. This would not be out of the 
ordinary as other studies have shown overlapping roles for NR4A1 and NR4A3 in other 
tissues. It is of interest to determine if NR4A3 expression increases upon NR4A1 
knockdown. Perhaps NR4A3 partially rescues the effects of NR4A1 knockdown and 
therefore differentiation still occurs, albeit at a slower rate. In addition, a double 
knockdown of both NR4A1 and NR4A3 may have a more profound effect on 
differentiation by completely preventing the initiation of differentiation. A recent study 
found that knockdown of NR4A3 in HSMM blocked the formation of myotubes, 
suggesting that NR4A3 is required for skeletal muscle differentiation [504].  
 
The regulation and function of NR4A1 during differentiation is of interest. 
Although NR4A1 does not appear to be a mechanism for ZNF148, that does not mean 
that ZNF148 is not a mechanism for NR4A1. ZNF148 may need to be suppressed during 
differentiation in order for NR4A1 expression to increase. We found that ZNF148 mRNA 
levels are unchanged during differentiation (data not shown), however its activity may 
still be suppressed. A proteomics study performed in our lab shows that ZNF148 protein 
levels decrease by almost 25% during LHCN differentiation (data not shown). Reduced 
ZNF148 activity would result in the inability to transcriptionally inhibit NR4A1, which 
would result in increased NR4A1 expression. The mechanism by which NR4A1 
potentially enhances differentiation is likely through transcriptional activation of genes 
important for the initiation and progression of the myogenic program as depicted in 
Figure 5-2. NR4A1 has been shown to induce expression of CKM, although it apparently 
does not bind the promoter [476]. Furthermore, 685 genes were recently identified by 
ChIP-seq as being directly regulated by NR4A1 in AML cells [505]. Interestingly, 
NR4A1 was found to transcriptionally activate ENO3 [505], a gene that our lab identified 
in the proteomics study to increase by 26 fold during muscle differentiation. ENO3 has 
been previously shown to increase during differentiation and has roles during muscle 
development [506]. Furthermore, ENO3 was found to be regulated by ETS transcription 
factors, which were recently discovered to interact with NR4A1 to transcriptionally 
activate NR4A1 target genes [505]. Therefore, it is quite possible that NR4A1 enhances 
myogenesis by promoting the expression of genes involved in this process. 
 
It may appear difficult to find a connection between the two main projects 
discussed here. The proliferative role of NR4A1 in cancer seems contradictory to its pro-
myogenic role in skeletal muscle. The key to these differential functions may depend on 
the expression levels of NR4A1. For instance in cancer, NR4A1 appears to be highly 
elevated. This substantial upregulation may be necessary for the proliferative effects of 
NR4A1. Conversely, NR4A1 expression increases during skeletal muscle differentiation 
(only in LHCN), although not to the same degree as in cancer. During normal muscle 
differentiation, NR4A1 may be acting as a co-driver to ensure the smooth and timely   
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Figure 5-2. Overview of the myogenic program. 
Muscle differentiation begins with mesodermal progenitors that express Pax3 and Pax7. 
Transcriptional activity by Myf5 allows the cells to either progress into brown adipose or 
into myoblasts after the addition of MyoD activity. Other transcription factors such as 
myogenin and possibly NR4A1 allow the cells to become myocytes. These cells fuse into 
multinucleated myotubes that will make up the muscle fibers. 
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differentiation of skeletal muscle cells, most likely by transcriptionally activating genes 
involved in myogenesis.  
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APPENDIX. SUPPLEMENTAL DATA FOR CHAPTER 3 
 
 
Figure A-1. miR-124 decreases NR4A1 expression in miRNA array.   
The Cancer miRNAs Transcriptome PCR Array containing cDNA from HeLa cells 
transfected with one of the 90 cancer-related miRNAs, as described in Materials and 
Methods, was used to detect NR4A1 expression and identify miRNAs that target NR4A1. 
The resulting gene expression of NR4A1 is displayed as Log2 with horizontal lines 
indicating the cutoff value (as suggested by the manufacturer) at which NR4A1 gene 
expression is considered to be significant. Three miRNAs, including miR-124, were 
found to decrease NR4A1 expression.  
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Figure A-2. NR4A1 and miR-124 have inverse expression in granule neurons.  
NR4A1 and miR-124 expression were measured in granule neuron precursors (GNPs) 
harvested from P7 mice. The GNPs were cultured for 24 hours, allowing enough time for 
the cells to differentiate (GNP diff.) before being collected for expression analysis. The 
fold change for the GNPs was set to 1. The internal control for NR4A1 was GAPDH and 
the control for miR-124 was snoRNA 202. The data shown are the average of 3 
independent experiments with the average Ct values indicated below each graph. * 
indicates p < 0.0001.  
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Figure A-3. An inhibitor of miR-124 increases NR4A1 activity.  
Daoy cells were transfected with the NR4A1-3ʹUTR reporter plasmid (NR4A1-3ʹUTR-
Luc) and either the Exiqon miR-124 inhibitor at the indicated concentrations or the 
control molecule (Cntrl), resulting in increased luciferase activity as the concentration of 
the inhibitor increased. Data shown are representative of 2 independent experiments. * 
indicates p < 0.05.  
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Figure A-4. miR-124 decreases levels of NR4A1 target genes in 293T cells.  
Transfection of 293T cells with miR-124 decreased the levels of NR4A1 and its target 
genes, E2F1, BIRC5 (survivin), TXNDC5, and CDK4, compared to those of cells 
transfected with the vector control (MR03). The data shown are the average of 3 
independent experiments. * indicates p < 0.01.  
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Figure A-5. NR4A1 knockdown decreases cell viability and proliferation.  
(A) Daoy cells were transfected with 20 nM of the individual siNR4A1_4 or non-
targeting control (NT), and cell viability was measured via the CellTiter-Glo assay every 
day for 4 days. Viability for each day was normalized to that of Day 0 (0 hours), and 
statistical significance was calculated for each day; *p < 0.0001. (B) Cells were stained 
with crystal violet every day for 4 days to measure proliferation over time. The 
absorbance was measured and normalized to that of Day 0 (0 hours). The statistical 
significance was calculated for each day; *p < 0.01. (C) Proliferation was monitored via 
the IncuCyte live-cell imager. Cell confluence was averaged, with 4 replicates of each 
condition; *p < 0.0001. (D) NR4A1 mRNA was significantly (p < 0.0001) decreased after 
transfecting Daoy cells with siNR4A1_4. (E) Images shown for each NT and siNR4A1_4 
panel over 5 days are the same image view within the same well and are representative of 
3 independent experiments with 4 wells for each condition. These images correspond to 
the data in C. Data shown in D are the average of 4 independent experiments. Data shown 
in A and B are representative of 3 independent experiments, and data in C and E are 
representative of 2 independent experiments.  
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